Source: The Conversation (Au and NZ) – By Meru Sheel, Associate Professor and Epidemiologist, Infectious Diseases, Immunisation and Emergencies (IDIE) Group, Sydney School of Public Health, University of Sydney
Five years ago, COVID was all we could think about. Today, we’d rather forget about lockdowns, testing queues and social distancing. But the virus that sparked the pandemic, SARS-CoV-2, is still circulating.
Most people who get COVID today will experience only a mild illness. But some people are still at risk of severe illness and are more likely to be hospitalised with COVID. This includes older people, those who are immunocompromised by conditions such as cancer, and people with other health conditions such as diabetes.
Outcomes also tend to be more severe in those who experience social inequities such as homelessness. In the United Kingdom, people living in the 20% most deprived areas have double chance of being hospitalised from infectious diseases than those in the least deprived areas.
How many cases and hospitalisations?
In Australia, 58,000 COVID cases have been reported so far in 2025. However, testing rates have declined and not all positive cases are reported to the government, so case numbers in the community are likely much higher.
Latest data from FluCan, a network of 14 hospitals, found 781 people were hospitalised for COVID complications in the first three months of the year. This “sentinel surveillance” data gives a snapshot from a handful of hospitals, so the actual number of hospitalisations across Australia is expected to be much higher.
However, COVID peaks aren’t just necessarily seasonal. Over the past few years, peaks have tended to appear around every six months.
What are the most common COVID symptoms?
Typical early symptoms of COVID included fever, cough, sore throat, runny nose and shortness of breath. These have remained the most common COVID symptoms across the multiple variant waves.
Early in the pandemic, we realised COVID caused a unique symptom called anosmia – the changed sense of taste or smell. Anosmia lasts about a week and in some cases can last longer.
Anosmia was more frequently reported from infections due to the ancestral, Gamma, and Delta variants but not for the Omicron variant, which emerged in 2021.
However, loss of smell still seems to be associated with some newer variants. A recent French study found anosmia was more frequently reported in people with JN.1.
But the researchers didn’t find any differences for other COVID symptoms between older and newer variants.
Should you bother doing a test?
Yes. Testing is particularly important if you experience COVID-like symptoms or were recently exposed to someone with COVID and are at high-risk of severe COVID. You might require timely treatment.
If you are at risk of severe COVID, you can see a doctor or visit a clinic with point-of-care testing services to access confirmatory PCR (polymerase chain reaction) testing.
Rapid antigen tests (RATs) approved by Australia’s regulator are also still available for personal use.
But a negative RAT doesn’t mean that you don’t have COVID – especially if you are symptomatic.
If you do test positive, while you don’t have to isolate, it’s best to stay at home.
If you do leave the house while experiencing COVID symptoms, minimise the spread to others by wearing a well-fitted mask, avoiding public places such as hospitals and avoiding contact with those at higher risk of severe COVID.
How long does COVID last these days?
In most people with mild to moderate COVID, it can last 7–10 days.
Symptomatic people can spread the infection to others from about 48 hours before you develop symptoms to about ten days after developing symptoms. Few people are infectious beyond that.
But symptoms can persist in more severe cases for longer.
A UK study which tracked the persistence of symptoms in 5,000 health-care workers found symptoms were less likely to last for more than 12 weeks in subsequent infections.
General fatigue, for example, was reported in 17.3% of people after the first infection compared with 12.8% after the second infection and 10.8% following the third infection.
Unvaccinated people also had more persistent symptoms.
Vaccination against COVID continues to be one of the most effective ways to prevent COVID and protect against it. Data from Europe’s most recent winter, which is yet to be peer reviewed, reports COVID vaccines were 66% effective at preventing symptomatic, confirmed COVID cases.
Most people in Australia have had at least one dose of the COVID vaccine. But if you haven’t, people over 18 years of age are recommended to have a COVID vaccine.
Boosters are available for adults over 18 years of age. If you don’t have any underlying immune issues, you’re eligible to receive a funded dose every 12 months.
Boosters are recommended for adults 65–74 years every 12 months and for those over 75 years every six months.
Adults over 18 years who are at higher risk because of weaker immune systems are recommended to get a COVID vaccine every 12 months and are eligible every six months.
Check your status and eligibility using this booster eligibility tool and you can access your vaccine history here.
A new review of more than 4,300 studies found full vaccination before a SARS-CoV-2 infection could reduce the risk of long COVID by 27% relative to no vaccination for the general adult population.
With ongoing circulation of COVID, hybrid immunity from natural infection supplemented with booster vaccination can help prevent large-scale COVID waves.
Meru Sheel receives funding from National Health and Medical Research Council and Department of Foreign Affairs and Trade. She serves on WHO’s Immunization and Vaccines Related Implementation Research Advisory Committee (IVIR-AC)
When happy couple Charlotte and Matthew Harrison tied the knot in Temple Newsam House’s stunning Picture Gallery, it was a love story more than a century in the making.
The historic ceremony saw the newlyweds become the first people to be married in the gallery’s beautiful surroundings in over a hundred years.
Originally designed centuries ago to act as an “indoor garden” for the house’s aristocratic residents, the room’s spectacular floral theme instead became the ideal backdrop for what was a dream wedding day.
The couple, who met five years ago, chose the house as a venue after falling in love with the colourful gallery, which has only recently been made available for ceremonies.
Charlotte said: “We spend a lot of our time at Temple Newsam both together and with friends and when we heard they did weddings, we thought we’d check it out before making a decision.
“We love visiting stately homes and historic sites and when we saw the picture gallery we immediately fell in love and immediately knew it was just us. The room is absolutely stunning and steeped in history and was the perfect backdrop for our wedding.”
She added: “The wedding day was everything I have ever dreamed of and more. All of our guests commented on what a beautiful venue it was and how much they enjoyed the wedding. It was genuinely a dream come true.”
The couple were joined on their special day by family, friends and 20-month-old son Blake.
After meeting online during the Covid pandemic, Charlotte and Matthew had their first date at The Red Kite in Wakefield, where Matthew’s difficulties parking his car followed by some takeaway donuts made for an evening that was both sweet and memorable.
Almost five years later, Matthew, 33, popped the question on Christmas Eve at their home in Apperley Bridge, with a custom-designed ring and specially made scratch card.
Charlotte said: “It’s our family Christmas tradition to get scratch cards so I didn’t think anything of it- it looked super realistic- and then it had three ring symbols and Matt got down on one knee and asked me to marry him.”
Now the couple’s romantic story has become part of Leeds history, entering the record books at the 500-year-old mansion as the first couple to be married in the Picture Gallery since the house passed into public ownership in 1922.
Matthew said: “We’re honoured to be the first couple to be married there in over a century. We didn’t realise what a historic moment it was not just for us, but for Temple Newsam too and to be a part of that just made our day even more special. Temple Newsam has always held a fond place in our lives but the fact we can now be a part of its history is truly humbling.”
Charlotte added: “On a personal note, as a bit of a history nerd I’m genuinely thrilled that I can be a part of the history of the house.”
A Grade I listed mansion house, Temple Newsam House is one of the country’s finest examples of its kind, seen as equally significant to Hampton Court, and was a family home for much of its history.
Owned by Leeds City Council since 1922, Temple Newsam has built one of the most significant decorative art collections in the UK.
Councillor Salma Arif, Leeds City Council’s executive member for adult social care, active lifestyles and culture, said: “We’re absolutely thrilled to have played our part in this special and historic occasion and to have made Charlotte and Matthew’s special day so memorable.
“Our museums and galleries really are a beautiful setting for a wedding and it’s wonderful to see couples tying the knot there and becoming part of the story of these amazing sites.”
Source: United States Senator Joni Ernst (R-IA)
Published: May 6, 2025
Order comes after Ernst fought for years to end batty experiments of pandemic potential.
WASHINGTON – U.S. Senator Joni Ernst (R-Iowa) released the following statement after President Donald Trump signed an executive order to ban all federal funding of risky gain-of-function research in China, Iran, and other countries and blocking all federal funding for foreign research that could cause another pandemic.
“I have been fighting for years to end the insane practice of sending tax dollars to China for sketchy pseudoscience,” said Ernst. “Thankfully, President Trump is ending the batty experiments, like those conducted in Wuhan, that are dangerous and wasteful. This is a great win for the American people and common sense. I will continue working to expose and halt all taxpayer-funded risky research of pandemic potential in malign foreign countries!”
Background:
Ernst has led the charge in Washington to stop tax dollars from being sent for risky research overseas.
An Ernst-requested investigation exposed how EcoHealth sent over $1 million U.S. tax dollars to the Wuhan Institute of Virology for risky experiments on bat coronaviruses. She also secured an audit by the Department of Defense’s Inspector General of risky research in China paid for by the Pentagon and hidden from the public by Biden’s Pentagon.
She fought to permanently debar the Wuhan Institute of Virology and defund EcoHealth Alliance from receiving U.S. tax dollars.
Ernst efforts also led to the Department of Health and Human Services (HHS) defunding EcoHealth and promising to cut off any taxpayer dollars used for research of pandemic potential.
In her $2 trillion blueprint to slash waste in Washington, Ernst pointed to the millions being sent to China for secretive risky research.
Last month, she introduced the AFAR Act to end the insane practice of funding sketchy animal experiments in China with American tax dollars. Ernst also introduced the TRACKS Act to require every penny sent to foreign adversaries or entities of particular concern, such as terrorist groups including the Taliban, to be accounted for and disclosed to the public for scrutiny.
Eight Welsh businesses celebrated in The King’s Awards for Enterprise
Welsh recipients announced in third year of The King’s Awards for Enterprise – the UK’s most prestigious business awards.
The King’s Award for Enterprise. Recipients from Wales.
Businesses from Bridgend to Wrexham recognised, with each playing a key role in the UK Government’s mission for economic growth.
Winners across three different categories: Innovation, International Trade and Sustainable Development.
The recipients of The King’s Awards for Enterprise have been announced today [6 May], celebrating the achievements of leading businesses from across the UK and Channel Islands.
Eight Welsh businesses across a range of different sectors have been recognized by His Majesty The King as among the best in the country, highlighting the ambition, ingenuity, and success of our diverse business community.
The businesses awarded cover a variety of sectors including industrial lasers, medical equipment, and baking, and are based around the country, from Wrexham to Bridgend and Welshpool.
One Welsh company was awarded for their innovative practices, five for their achievements in international trade and one for their sustainable development.
By supporting more people into work, developing new innovations and exporting the best Britain has to offer around the world, businesses like these play a key role in the UK Government’s mission to go further and faster for economic growth, and put more money in more working people’s pockets as part of the Plan for Change.
Gareth Thomas, Minister for Services, Small Businesses and Exports said:
There are some excellent Welsh businesses recognised in this year’s King’s Awards for Enterprise: from Spectrum Technologies’ pioneering laser equipment to Bluestone Resort’s commitment to environmental responsibility.
I wish the winners every success as they continue to grow, innovate and prosper, and commend the invaluable contributions they have already made to communities at home in Wales and abroad, helping to boost the UK economy.
Secretary of State for Wales Jo Stevens said:
I congratulate all eight Welsh businesses who have won awards. From baking to medical devices to sustainable holidays, their work shows the best of business right across Wales, producing and exporting high quality products and services.
By working with talented Welsh enterprises to create well-paid local jobs and economic growth, the UK Government is delivering on its Plan for Change.
This year’s recipients include Spectrum Technologies, a global leader in the supply of industrial laser wire-processing equipment for the aerospace industry. Based in Bridgend, they have been recognised in the International Trade category.
Dr Peter Dickinson, Chairman and Chief Technology Officer at Spectrum Technologies, said:
Spectrum is very excited and proud to be a winner of the King’s Award for Enterprise. The Company faced huge challenges with Covid but our team of employees have really pulled together and helped turn a difficult situation around, more than doubling sales over the last few years.
The King’s Award is a tribute to their combined efforts, as well as a reflection on the company’s global market-leading position supplying specialised laser wire processing equipment to the aerospace industry.”
Bluestone Resort is situated in the heart of the Pembrokeshire countryside. The park has been designed to reconnect families with nature in a responsible fashion, and as such they have received an award in the Sustainable Development category.
William McNamara OBE, CEO and Founder of Bluestone, said:
Receiving the King’s Award for Enterprise in Sustainable Development is a hugely exciting and rewarding milestone for everyone at Bluestone National Park Resort in Pembrokeshire.
Our ethos is centered on the three pillars of sustainable development: actively protecting natural ecosystems, growing the local economy and supporting local communities. This has become our operational blueprint. The King’s Award for Enterprise in Sustainable Development gives us many reasons to celebrate, recognising the importance of our work as we continue to protect our planet for future generations.”
The King’s Awards for Enterprise were previously known as The Queen’s Awards for Enterprise and were renamed two years ago to reflect His Majesty The King’s desire to continue the legacy of HM Queen Elizabeth II by recognising outstanding UK businesses. The Award programme, now in its 59th year, has awarded over 8,000 companies since its inception in 1965.
His Majesty’s Lord Lieutenants – the King’s representatives in each county – will be presenting the Awards to businesses locally throughout the year. One representative from each winning business will also be invited to a special royal reception event.
Eligible businesses are free to apply for one or more categories. The recipients pass a robust assessment process, judged by experts from industry, academia, the voluntary sector, a representative from the Welsh Government and senior officials in Whitehall. On that basis, each year, The King’s Awards for Enterprise recipients are recommended by the Prime Minister.
Richard Harris, Head of Trade at the Welsh Government and a judge on this year’s panel commented:
It’s an absolute privilege to represent Wales as a judge on the Kings Awards and reviewing and appraising the applications which seem to grow in quality year on year never fails to impress.
The Kings Award is the gold standard, it means something, for me it’s the benchmark award for quality that can literally open doors and start conversations across the world, enabling companies to access opportunities that ordinarily might not be available and win business.
A brand-new enterprise centre has opened in Stoke-on-Trent to support young entrepreneurs.
Stoke-on-Trent City Council has been working with Launch It over the past two years to find a suitable home for its first Midlands venture.
Now the charity, which provides young people with the space and support they need to start a business and develop their skills, has moved into the grade II-listed Longton Town Hall building on Times Square.
The enterprise centre aims to drive the regeneration of Longton and the wider area by providing affordable workspaces, business development support, skills training, mentoring, funding opportunities and guidance to help young people succeed in their respective industries.
Speaking at the launch event last week, Councillor Chris Robinson, cabinet member for housing and planning and ward councillor for Longton, said: “I am really proud that Launch It have chosen to set-up in Longton. Longton Town Hall is an important heritage building. I’m pleased that we have been able to work with them to bring it back into modern-day use, while creating something of real benefit to our young people.
“Being able to attract an organisation such as Launch It shows me that we are moving in the right direction and shows the young people of the city that the support and guidance they need to start a business in Stoke-on-Trent is available to them.
“This will also bring economic benefits to Longton which is already bucking the trend. I look forward to working with the Launch It team and I wish them all the best for the future.”
Anya Cummings, chair of the Board of Trustees at Launch It Stoke-on-Trent, said: “We are beyond excited to officially open the doors to Launch It Stoke-on-Trent and welcome young founders, small business owners, supporters and the local community who will be part of this vibrant space.
“Bringing Launch It’s 25-year legacy of helping break barriers to thriving in entrepreneurship to Stoke-on-Trent marks the beginning of an exciting new chapter – one where ambition meets opportunity, and young entrepreneurs can help shape the future of this vibrant city.”
The former upper floor ballroom at Longton Town Hall was refurbished in 2023 to create a new enterprise space to support small businesses on the back of the Covid-19 pandemic.
It was part of a trio of city council properties which were identified for refurbishment as part of the then-government’s Getting Building Fund grant scheme.
The historic building now boasts 20 state-of-the art studios offices, open-plan co-working spaces, meeting rooms, Zoom booths and a small kitchen and toilet area.
Preston City Council will proudly mark both VE Day and VJ Day in 2025 with a series of commemorative events in the city centre, following requests from local veterans and community members.
This year, in recognition of the 80th anniversary of the end of the Second World War, the city’s focus will shift from the usual Armed Forces Day to these two historically significant dates.
VE Day, celebrated on Thursday, 8 May, commemorates the end of the war in Europe. Starting at 8:45pm at The Flag Market with speeches, performances from vintage singer Hattie Bee, music from Brindle Brass Band and a commemorative beacon lighting at 9:30pm directly followed by the National Anthem.
VJ Day marks the surrender of Japan and the true end of WWII. will be observed this year on Saturday, 16 August, slightly later than its official anniversary of 15 August, to allow for wider public participation over the weekend.
This year on Friday the 15 August, Victory over Japan or VJ Day which was the day all hostilities ceased, the traditional commemoration ceremony will be held at the Commonwealth War Graves Commission memorial in Preston Cemetery to remember those “who gave their tomorrows so we could have our todays.” This ceremony has been held without fail every year since 1947, including socially-distanced events during Covid, and in keeping with previous years will be led by The Right Worshipful Mayor of Preston, Councillor Phil Crowe.
Join in an unforgettable Victory Over Japan Day (VJ Day) in Preston, where history comes to life through a range of events and performances, beginning with a military parade. Expect performances and workshops, and vintage music transporting you back in time with songs from the wartime period.
Don’t miss this opportunity to pay tribute to the heroes of World War Two and celebrate 80 years of courage, sacrifice, and resilience.
Councillor Close, Armed Forces Champion at Preston City Council, said:
“It’s important that we remember both VE Day and especially VJ Day, which marked the end of WWII, and the immense sacrifices made by our armed forces and their families.
By commemorating these events in Preston, especially on the 80th anniversary of the end of World War II, we honour those who gave so much. The VJ Day event on 16 August allows us to welcome more people to reflect, remember, and show their support.”
Colonel David Waters, President Lancashire Armed Forces Association said:
“It would be easier to generalise and talk about freedom and democracy, but in this last week, we’ve had the anniversary of the liberation of Belsen Concentration Camp, and if that was to concentrate
your mind on something, it’s about what people did lose in Europe through the occupation of the Germans, and so that in itself is a reason to celebrate VE Day.”
These events aim to bring together veterans, families, and the wider community in remembrance and gratitude. Full details of the programme will be released in the coming months.
The Government’s proposed amendments to the Equal Pay Act 1972 represent a major setback for pay equity and a breach of women’s fundamental rights, says leading gender advocate Dellwyn Stuart, co-founder of Mind the Gap and CEO of YWCA Auckland.
“This move takes us backwards, not forwards,” says Ms Stuart. “It remains a violation of women’s human rights to be paid unfairly, and this Government is dismantling decades of hard-won progress to close the gender pay gap.”
Female-dominated professions – including care work, nursing, and early childhood education – continue to be underpaid and undervalued compared to traditionally male-dominated sectors, despite their essential role in the wellbeing of Aotearoa.
“We saw during Covid-19 how vital these roles are to society. Nurses and carers were rightly recognised as essential. Now, those same workers are being told that fair pay is off the table – that their aspirations for financial security and dignity at work don’t count,” says Ms Stuart.
She warns that these changes will likely worsen the existing workforce crisis: “Skilled workers will continue to seek better opportunities overseas, leaving our health and social systems even more vulnerable.
“With many pay equity claims involving government-employed workforces, Ms Stuart points to the contradiction at the heart of current policymaking: “This coalition government is actively perpetuating pay discrimination. At the same time, the Minister for Women is travelling the country asking businesses to close their pay gaps. How can the Government expect the private sector to commit to pay equity when it is not leading by example?”
The gender pay gap remains a significant issue in Aotearoa New Zealand, particularly affecting Māori and Pacific women, who are already over-represented in lower-income statistics. While the national gender pay gap sits at 8.2%, it rises to 15% for Māori women and 17.3% for Pacific women (Source: Ministry for Women, 2024).
“If we’re serious about fairness and decency in this country, we need to properly value the work of those who contribute the most to the wellbeing of our society,” say Ms Stuart.
Question for written answer E-001675/2025 to the Commission Rule 144 Gerald Hauser (PfE)
Scientific publications document cases of liver damage following vaccination against COVID-19, including immune-mediated hepatitis, acute liver cell injury and liver impairment in transplant patients. Here are a few examples:
– Liver injury following SARS-CoV-2 vaccination: A multicenter case series[1]
– Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome[2]
– Histological and serological features of acute liver injury after SARS-CoV-2 vaccination[3]
– Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines[4]
– Severe de novo liver injury after Moderna vaccination – not always autoimmune hepatitis[5]
Not only can liver damage be caused by mRNA vaccination, but the vaccines also have a wide range of other side effects.
1.In hindsight, what does the Commission make of the scientific diligence shown in authorising the mRNA vaccines in view of the wide range of side effects they have?
2.Are any investigations currently being carried out by the Commission or subordinate EU authorities into the safety of mRNA vaccines?
3.Were potential hepatotoxicity, genotoxicity, cardiotoxic effects, immunotoxicity, neurotoxic effects and possible long-term effects on liver function and genetic integrity investigated when the mRNA vaccines were authorised?
PROTECTING AMERICANS FROM DANGEROUS GAIN OF FUNCTION RESEARCH: Today, President Donald J. Trump signed an Executive Order to improve the safety and security of biological research in the United States and around the world. This Executive Order:
Ends any present and all future Federal funding of dangerous gain-of-function research in countries of concern like China and Iran and in foreign nations deemed to have insufficient research oversight.
Empowers American research agencies to identify and end Federal funding of other biological research that could pose a threat to American public health, public safety, or national security.
Prohibits Federal funding from contributing to foreign research likely to cause another pandemic. These measures will drastically reduce the potential for lab-related incidents involving gain-of-function research, like that conducted on bat coronaviruses in China by the EcoHealth Alliance and Wuhan Institute of Virology.
Protects Americans from lab accidents and other biosecurity incidents, such as those that likely caused COVID-19 and the 1977 Russian flu.
ESTABLISHING SAFE AND SECURE OVERSIGHT OF DANGEROUS GAIN OF FUNCTION RESEARCH IN THE UNITED STATES: This Executive Order will increase the safety and security of biological research for Americans without impeding U.S. innovation.
For decades, policies overseeing gain-of-function research on pathogens, toxins, and potential pathogens have lacked adequate enforcement, transparency, and top-down oversight. Researchers have not acknowledged the legitimate potential for societal harms that this kind of research poses.
The Biden Administration allowed dangerous gain-of-function research with insufficient levels of oversight and actively approved Federal life-science research funding in China and other countries.
The 2024 United States Government Policy for Oversight of Dual Use Research of Concern and Pathogens with Enhanced Pandemic Potential (“DURC/PEPP”) and the 2024 Framework for Nucleic Acid Synthesis Screening are the latest examples of inadequate policies that rely on self-reporting and fail to protect Americans from dangerous research practices.
This Order pauses research using infectious pathogens and toxins in the United States that may pose a danger to American citizens until a safer, more enforceable, and transparent policy governing such research can be developed and implemented. It directs the Director of the Office of Science and Technology Policy (OSTP) and the National Security Advisor (NSA) to work with funding agencies to develop such a policy within 120 days.
Unlike previous policies, this Order contains enforcement and reporting mechanisms that will strengthen oversight and discourage subjective interpretation of policies that researchers have used in the past to evade biosafety and biosecurity oversight.
SAFEGUARDING THE FUTURE AND PROMOTING AMERICAN BIOTECHNOLOGY DOMINANCE: President Trump is driving us into the Golden Age of American Innovation that will lead us to a safer, healthier, and more prosperous America.
This Order protects Americans from dangerous gain-of-function research that manipulates viruses and other biological agents and toxins, but it does not impede productive biological research that will ensure the United States maintains readiness against biological threats and continues to drive global leadership in biotechnology, biosecurity, and health research.
President Trump has long theorized that COVID-19 originated from a lab leak at the Wuhan Institute of Virology and has consistently pushed for transparency in investigating its origins.
Source: United States House of Representatives – Congressman Morgan Griffith (R-VA)
U.S. President Donald J. Trump signed an Executive Order to halt U.S. federal funding of gain-of-function research in overseas countries, like China and Iran, without proper oversight measures. In response to the Executive Order, U.S. Congressman Morgan Griffith (R-VA) issued the following statement:
“President Trump’s decisive action against gain-of-function research is a significant step towards greater government agency accountability. While this news is welcomed by many who have closely investigated COVID-19 origins, I believe future congressional action is essential to monitoring gain-of-function research of concern, reforming our public health agencies and protecting American life from risky experiments that involve dangerous virus transmission in humans.”
BACKGROUND
In the 118th Congress, Rep. Griffith chaired the House Committee on Energy and Commerce Subcommittee on Oversight & Investigations.
Rep. Griffith chaired hearings on various issues, including but not limited to topics of biosafety and risky research.
Rep. Griffith was the lead Energy and Commerce Member in numerous forums with public health officials that were in various leadership positions during the outbreak of COVID-19, including working closely with the Select Subcommittee on the Coronavirus Pandemic.
During this time, Chairman Griffith participated in closed-door transcribed interviews questioning former National Institute of Allergy and Infectious Diseases (NIAID) Director Dr. Anthony Fauci and questioning former National Institutes of Health (NIH) Director Dr. Frances Collins.
Rep. Griffith was also a key figure in examining EcoHealth Alliance President Dr. Peter Daszak.
EcoHealth is the company that received grants from NIAID which in turn gave subgrants to the Wuhan Institute of Virology to conduct research on Coronavirus evolution and transmission.
Because of questions asked by Rep. Griffith related to significant inconsistencies and delays in required reports, among others, the U.S. Department of Health and Human Services recently announced that Dr. Daszak and EcoHealth Alliance would be debarred for five years, cutting them off from U.S. federal funding.
In January of 2025, the Wall Street Journal reported that President Trump was considering an Executive Order to halt federal funding to gain-of-function research. In response, Rep. Griffith called on President Trump to scrutinize the country’s national gain-of-function research policy.
Some of Rep. Griffith’s e-newsletters on these topics can be found here and here.
In March, Rep. Griffith introduced the Risky Research Review Act and the Royalty Transparency Act to rein in the federal health bureaucracy.
President Donald J. Trump’s relentless pursuit of an American manufacturing renaissance is “boosting demand for some U.S.-made goods, with smaller players reaping the early benefits,” writes The Wall Street Journal, as companies onshore production and buy their products in America.
“‘We are swamped. We are running 24 hours a day, seven days a week in both Chicago and Cleveland,’ said Jack Schron, president of Jergens Inc., which makes manufacturing tools, including industrial screwdrivers, clamps and hoists. Schron said his factories in Ohio and Illinois are ‘going like gangbusters,’ partly owing to new orders from customers looking to avoid paying import tariffs.”
“Donny Chaplin, president of Grand River Rubber & Plastics in Ashtabula, Ohio, said he has seen a rush of new inquiries and orders. Two previous customers that had switched to Chinese suppliers a few years ago came back in recent days wanting to buy rubber gaskets from Grand River again, for the plastic pails they manufacture. Three manufacturers of oil filters also got in touch, wanting to shift business from China, with two already placing orders. All together, the new business will be worth about $5 million a year if it is completed, or roughly 10% of Grand River’s revenue. That might require the company to hire new employees and expand production lines.”
“The tariffs are a lifeline for the U.S. companies that sprang up during the Covid-19 pandemic to produce face masks, rubber gloves and other personal protective equipment, after shipments from Asia declined. The companies struggled in the pandemic’s aftermath, when hospitals and clinics abandoned U.S. manufacturers and returned to lower-cost suppliers in China, U.S. executives said. But new U.S. tariffs on rubber gloves from China have doubled the price from a few months ago, and ‘the folks that are relying on China are scrambling for other sources,’ said Alan Rust, chief growth officer for SafeSource Direct … ‘We were getting stiffed for a very long time, but just recently we’ve been getting a lot more inquiries.’”
“Employees for Massachusetts-based AccuRounds are working overtime to accommodate rising orders for the company’s shafts, valves and other steel components. The company recently added two customers that had shifted business from AccuRounds to suppliers in Singapore and China in recent years. First-quarter sales were 20% higher from a year earlier, said Chief Executive Michael Tamasi.”
“Michigan-based Whirlpool, which assembles 80% of its U.S. appliances at domestic factories, says its Asian competitors have had an unfair advantage, as they manufacture their appliances overseas but haven’t been paying import tariffs on them since 2023, when one imposed during Trump’s first term expired. Those rivals’ access to cheaper components and steel in Asia helps give them a $150 retail price advantage on washers, Whirlpool says. Chief Executive Marc Bitzer said the latest tariffs on imported assembled appliances should help close the price gap. ‘The tariffs will finally help create a level playing field for Whirlpool,’ he said in April during a call with analysts.”
“At the local Excel Dryer plant, William Gagnon, the chief operating officer, is unfazed. In fact, President Donald Trump’s import taxes so far have been nothing but good news for one of the world’s largest makers of restroom hand dryers. Gagnon, 48, credits Trump’s first-term tariffs with changing the math on production location decisions … the president’s second-term ‘reciprocal’ tariffs might result in the elimination of trade barriers that prevent Excel’s high-velocity hand dryers from dominating markets in countries such as Brazil and Australia … By making foreign goods more expensive, the import taxes make domestic suppliers more competitive while also discouraging Americans from purchasing cheap Chinese copies of Excel’s hand dryers. The tariffs also offer hope of prying open foreign markets … The tariffs Trump imposed on China this year also have brought more work home for one of Excel Dryer’s local suppliers: Double A Molding in Monson, Massachusetts … As Trump escalated his trade spat with China in recent weeks, Double A felt the effects.”
The UAB study showed that the intervention resulted in statistically significant and very large benefits on its primary measures of performance and satisfaction with daily activities.
It also showed significant benefits in many secondary measures, including large to very large benefits on depressive, fatigue, and brain fog symptoms, as well as a significant benefit in brain processing speed, and a trend toward large benefits on anxiety symptoms. No significant change was noted in a measure of global cognition.
Perhaps, most strikingly, the researchers reported that eighty percent of the non-retired participants in the intervention group returned to work, and none in the control group.
This was a modest-sized study designed primarily to assess feasibility and to help scope follow-on studies. The researchers enrolled 16 community residents, who were three or more months past COVID infection, with mild cognitive impairment and with dysfunction in the performance of instrumental activities of daily living. Participants were randomly assigned to the intervention or to a wait-list control.
The intervention is based on the science of neuroplasticity, which has established that intensive, repetitive, and progressively challenging activities can drive beneficial changes to the brain. The approach is based on the seminal work of Dr. Michael Merzenich, who upended the field of brain science four decades ago, by showing that brains remain plastic — capable of chemical, physical and functional change — at any age.
After discovering lifelong plasticity, Dr. Merzenich first harnessed plasticity in his co-invention of the cochlear implant to restore hearing to hundreds of thousands of people. For the past three decades, he has focused on creating computerized brain exercises to improve brain health and function. He is the Co-Founder and Chief Scientific Officer of the company that makes the BrainHQ exercises.
The intervention in this study reflects further work in plasticity of two distinguished UAB faculty members. Dr. Karlene Ball pioneered plasticity-based exercises to address age-related cognitive decline. Her UAB colleague, Dr. Edward Taub, developed plasticity-based, constraint-induced movement therapy to address movement disorders. His supportive and progressively challenging coaching inspired the coaching used in this study.
Prior studies of BrainHQ exercises in older adults, and in patients with various health conditions, (cancer, heart failure, multiple sclerosis, schizophrenia, mild cognitive impairment) suggested the kind of improvements seen in this study (in cognition, daily activities, depressive symptoms, stress, fatigue, and employment status). However, the magnitude of the improvements in this study were quite large as compared to some prior studies.
“That may be because this study population had substantial deficits with room for substantial improvement, or it may be there is extra benefit from combining the exercises with this type of coaching,” commented Dr. Henry Mahncke, CEO of Posit Science. “Either way, it suggests that brain training is a promising approach to helping people with Long COVID.”
“It’s been a long road to address Long COVID,” observed Dr. Mahncke. “We hope this will be a turning point in identifying tools to address a condition that is often quite debilitating.”
BrainHQ exercises have shown benefits in more than 300 studies. Such benefits include gains in cognition (attention, speed, memory, decision-making), in quality of life (depressive symptoms, confidence and control, health-related quality of life) and in real-world activities (health outcomes, balance, driving, workplace activities). BrainHQ is offered by leading health and Medicare Advantage plans, by leading medical centers, clinics, and communities, and by sports, military, and other organizations focused on peak performance. Consumers can try a BrainHQ exercise for free daily at https://www.brainhq.com.
Distinguished audience, this conference, BRONCOCON 2025, has come not a day too soon because it addresses issues that are writing on the wall. Issues of huge contemporaneous relevance. It gives me immense pleasure. I take it as an absolute honour to inaugurate the 27th Annual Conference of the Indian Association for Bronchology. The Institute is known for its hallmark excellence in respiratory medicine and innovation.
I’m sure the deliberations will be extremely fruitful. There will be ideation, exchange of ideas and interaction amongst people who are dealing with this menace to humanity that is ballooning by the day. BRONCOCON, according to me, is bound to be a crucible of ideas, redefining the future of pulmonary care in India and beyond, and this is gaining urgency, this is gaining paramountcy, this is gaining absolute attention.
With over hundreds of brilliant minds dedicated to respiratory care, I’m reminded that each breath, that fundamental act of living that defines that we are living, is what your profession protects. You are protecting our lives. Your theme, very well thought out. Beyond the scope, evolving frontiers in pulmonary procedures. This demonstrates remarkable foresight because the issues are known to one and all.
Everyone is concerned and we live in a city where this dominates our mindset for months together. We know the evil consequences of this issue not being addressed. It is cancerous for society. Much beyond COVID, if we analyse the loss for our children, for our elderly citizens and for our youth, apart from those far before me.
The future of pulmonary care lies at the intersections of medicine, technology, environmental science, public policy and community engagement. All are vital to address this problem. Gone are the days when either education or solutions could be by stand-alone institutions. There has to be concerted effort. There has to be convergence of all stakeholders. They have to be on the same page to find resolution of a problem which is diagnosed by everyone in a city like Delhi and beyond. Pulmonologists and bronchologists have been silent sentinels of public health, moving to the frontline during, and who knows better than me, as Governor of the State of West Bengal. COVID-19, what a challenge it was.
I salute your tireless efforts across clinics, ICUs, labs, classrooms and policy-making arenas. When the challenge was so huge, humanity in a non-discriminatory fashion came to face this menace, home to one-sixth of humanity in the land of Atharva Ved, showed the way. We could easily find light at the end of a tunnel and also show light to about hundred other countries that are ever beholden to us. Indian pulmonology has transformed through growing clinical expertise, public awareness and technological adoption.
India, distinguished audience is a land which is witnessing at the moment accessibility to technology, adaptability to technology and technology delivering for the people at large, but in this field also much has to be negotiated. As I just indicated a while ago, our ancient texts, particularly Atharva Ved and envisions, health as a perfect balance of body, mind and spirit. It recognises breath as ‘pran’. If it goes, ‘pran’ doesn’t exist in us.
The vital life force connecting individual wellness with environmental harmony. The importance of health can be visualised. A talented person, a person with passion, mission, ability for execution, for public causes, can be severely handicapped on account of health not being in order.
So such a well-meaning person whose commitment is not in doubt, passion is on the right path, mission is for people at large, execution ability is recognised, he himself becomes a person in need and therefore health is all-important. Our traditional wisdom teaches that respiratory health is inseparable from nature’s equilibrium, reckless exploitation of nature. We are its trustees and we have become its owners and we are exploiting not for optimal need but for our greed.
A time for all of us to think. Our physical prowess, our financial power cannot determine how we use these resources which are meant not only for individual serving having means but have to be utilised equitably for one and all. It is time for us to go back to our wisdom and knowledge that is our treasure recognised by the globe. We have to see indigenous practices of seasonal living. Our elderly people always say to use vegetables which are being grown around the same time. Use fruits which are there around the same time.
Forest conservation and dietary wisdom align remarkably with modern preventive medicine. We therefore have to go back to our roots. No time is better than this because the might of Bharat is being realised, reckoned and recognised by the global powers, by the global fraternity. And it is in this context I remind the distinguished audience the time-tested science of ‘Yoga and Pranayama’. These offer profound solutions but imagine the Indian Prime Minister takes this vision to the global community, makes an appeal to the United Nations. The shortest time the largest number of nations converge to support it and we are now celebrating International Yoga Day.
The population on the planet is uniformly benefiting thereby. Then we have techniques like Anulom Vilom, Bhastrika, Kapalbhati and when I see these being demonstrated on television. I find many people instantly want to take to these, but I will appeal particularly to our youth, impressionable minds to learn it once for all. If you learn the technique once your approach will be stable, sustained, not tentative. These afford not solutions but are recipes for longevity. They enhance immunity, they generate us stress-free, our vitality goes up, the quotient of happiness is enhanced. This will obviously lead to higher productivity.
Modern research has validated that our ancient practices are scientific. Our ancient practices are extremely potent. They afford precautionary, preventive solutions. The integration of traditional wisdom into modern scientific research is the need of the time and I am sure those dealing with contemporary medicine research will address this issue. The surge in interventional pulmonology enables targeted life enhancing interventions. Deploying these at district level health care centres could accelerate our national tuberculosis elimination programme. If metros are fully equipped that is not a solution. We have to reach out up to district level, both in terms of availability and affordability. While lung cancer remains a leading cause of cancer mortality, early detection technologies not only offer hope but confidence that the problem can be addressed.
We must expand from the practice of medicine to the reach of medicine ensuring, as I said earlier, affordability and accessibility. Fortunately the government by affirmative policies has done much in this direction but it is the health and mindset of people of a nation that define the nation and health defines the mindset. If we believe and want everyone to believe that our mindset must be nationalistic, we must always keep nation first. No interest whatsoever personal, partisan or fiscal can have overriding impact or national interest but then that requires the first aspect.
Consider the lived realities and now I seek your attention. Look at the plight of children who are close to industrial areas. Look at those tender souls. The elderly exposed to biomass smoke. The farmer faces parali or crop burning issues. The factory worker inhales chemicals, dust. Invisible citizens whose lives are shaped by the air we breathe.
I still recall a person in another country handling the health department in another country saying a sick child is an assurance to the doctors for their work and pharmaceutical companies for survival. We don’t want that scenario. It will be too much for us to go for air purifiers. Selective solutions in democracy do not reflect well on democracy. Solutions have to be for one and all because equality is the hallmark of democracy and we have equality when iniquitous situations are contained in a systemic manner.
As indicated in one report just a year ago in February 2024, respiratory diseases continue India’s largest disease category and account for one-sixth of our population. Just imagine what a staggering figure it is. Asthma arises among children. COPD robs adults of productivity. Tuberculosis persists and tuberculosis is a situation that affects the entire family. Fortunately now the treatment is there. There was a time when there was no treatment. So what is more fundamental is diagnosis. Early diagnosis your treatments emanate easily. The psychological toll, just imagine someone suffering from TB, someone suffering from cancer, the psychological toll not on the only patient but on the family’s huge.
Fortunately now there is hand-holding for the physical part of it but then also much needs to be done. Then there is stigmatisation. Rather than hand-holding we keep to distance ourselves out of ignorance. Environmental factors include and who doesn’t know it, air pollution.
Just reflect today. Air pollution index in this city, you’ll be amazed. When you look at the desirable index and we’re getting away from it. But what is concerning is we are not serious about it. Like climate change, existential challenges, we don’t have another planet to live, but everyone thinks it is anybody else’s job. The job is of one and all. We are cliff hanging. We need to be awake. Then apart from air pollution, vehicular emissions. We don’t pool our resources. We would like to show our wealth by having as many cars as we can have. We have to find a systemic solution. Thankfully our public transport system is being strengthened. We are falling back on alternative automobile culture, but let’s do it while there is time.
Human behaviour, what we use, our level of nutrition and suddenly a new term has emerged in last few decades. Lifestyle disease is something which is correctionable at the level of an individual, at the level of the family, at the level of the society. The problems are compounded because they get in a stream making life of individuals difficult. But I am not in despair. I am full of hope, optimism and confidence. That when there is convergence of mind like yours, the mind that will ideate, the mind that will engage in research.
Let me caution you, research has to be authentic, research must be connected with ground results. Research is not meant for oneself or self, research is not to be for the self. Research is not assimilation. Research has to be real research that not only the nation but countries beyond us can take benefit of it.
Fortunately in our country there is a revolution of green energy, redotting our rural landscape massively but we need to do more on this. We need accelerated phasing out of old vehicles. People have to understand that an old vehicle has to be discarded for reasons that concern our health. Merely because an old vehicle is functional on the road, does not reflect on its road worthiness, that has to be done.
I said public transportation. We must take pride in using public transportation. Our ego should not come in between. In many countries this is done and here also the safest, fastest, surest way to reach an airport is through a metro. But that is something we need to make a habit of.
Look at our urban lungs – water bodies, forests and tree cover. In our Vedic culture we reward them, we worship them. Now we are using it for our own gain. We are destroying our respiratory system that nature has given to us. People go for indoor plants, air purifiers out of necessity. Not recognising that this is indicative of a deep malice that is permeating in the society. Your miniscule solution is temporary for you. You have to find a systemic solution. Systemic solution is one that improves the world.
I deeply appreciate the medical community in our country. Your role transcends healing, encompassing innovation, advocacy, education and inspiration. When we faced pandemic, this was demonstrated. People came with their own ideas and they were safe from Covid.
I therefore appeal to all of you that we must bridge medicine with data science, environmental studies, engineering and artificial intelligence. Artificial intelligence or let us put it in a broad term, disruptive technologies, these have entered our home, our way of life, our workplace, our research centres.
Disruptive technologies are much beyond the impact of industrial revolutions but the challenges have to be converted into opportunities. According to me, distinguished audience, it is a myth that this technology, when employed, will cut into human resource employability – No. You have to tame the technology, you have to use it for our advantage, and I’m sure you’ll work it out. You are working for a robust environment for us all. Your deliberations are bound to be absolutely wholesome for all of us.
Let us resolve on this day to build a future where every citizen breathes easily, breathes clean air, lives longer, and dreams bigger. Health is the first factor that deprives happiness. May your deliberations be fruitful and transformative.
‘सर्वे भवन्तु सुखिनः सर्वे सन्तु निरामयाः’ is something we have got from our scriptures to be practised.
I am grateful for the Vice-President here, who is also chairman of BRONCOCON 2025, Dr. Vivek Nangia, also Dr. R.P. Meena, the president, and the secretary, Dr. Amita Nene, for affording me this opportunity to interact with brilliant minds, minds that have passion without personal interest, a mission that is not selective, and execution that is uniform, that is helping one and all — ‘Vasudhaiva Kutumbakam.’
Source: The Conversation – Canada – By Jeffrey B. Meyers, Instructor, Legal Studies and Criminology, Kwantlen Polytechnic University
In the most non-controversial and basic sense, the rule of law means formal legality. The law binds citizens and governments. When it comes to nation states, law is enacted by democratically elected legislatures; legal statutes are openly available and sufficiently clear to follow. State actions can be judicially reviewed for compliance with a constitution.
In its more ambitious conceptualization, the rule of law can also be understood to include substantive human rights and equity. In Canada, The Constitution Act of 1982 references the rule of law in its preamble.
The modern Canadian iteration of the rule of law — which includes substantive ideas about human rights as well as Indigenous treaty rights — is based on liberal ideas shared by many countries, including, historically, the United States. What distinguishes a rule-of-law state from an authoritarian one to a large extent is whether state actions can be judicially reviewed for compliance with a constitution.
Although rule of law scholars debate the parameters of the concept of the rule of law, few would debate that what is happening during U.S. President Donald Trump’s second term presents anything other than a wholesale attack on the rule of law both domestically in the U.S and internationally.
I am a rule of law researcher, educator and lawyer. Since Trump was elected to his first term in 2016, I’ve relied on American scholars, from a variety of disciplines, to understand what is happening.
Both Stanley and Snyder explore the similarities between what is occurring in Trump’s America, Viktor Orban’s Hungary, Vladimir Putin’s Russia, Xi Jinping’s China and, equally chillingly, between Trump’s America and Adolf Hitler’s Germany. Even prior to the first Trump presidency, Stanley already asked in his 2015 book, How Propoganda Works, whether the U.S., “the world’s oldest liberal democracy,” might already have become a liberal democracy “in name only?”
In his 2018 book, The Road to Unfreedom: Russia, Europe, America, Snyder described Trump as a “sado-populist, whose policies were designed to hurt the most vulnerable people of his own electorate.”
Similarly, Snyder’s focus on the similarities between Trump and other authoritarian leaders, through their attachment to extreme illiberal ideologies, helped frame public discourse in the U.S. during the first Trump presidency. “Illiberal” does not imply conservative in opposition to “being liberal” (with the resonance of “leftist”); rather, it denotes a repudiation of liberal democracy, in the words of political scientist Thomas J. Main.
In the introduction to his bestselling 2020 book, How Fascism Works, Stanley wrote: “In recent years, multiple countries across the world have been overtaken by a certain kind of far-right nationalism; the list includes Russia, Hungary, Poland, India, Turkey and the United States.”
He explains the choice of the word “fascism” to speak about each of these countries, despite their differences of degree and context:
“I have chosen the label ‘fascism’ for ultra nationalism of some variety (ethnic, religious, cultural), with the nation represented in the person of an authoritarian leader who speaks on its behalf. As Donald Trump declared in his Republican National Convention speech in July 2016, ‘I am your voice.’”
In his similarly bestselling book, On Tyranny, published in 2017, Snyder wrote: “To abandon facts is to abandon freedom. If nothing is true, then no one can criticize power, because there is not basis upon which to do so. If nothing is true, then all is spectacle. The biggest wallet pays for the most blinding lights.”
Now that Trump is back in office, Stanley and Snyder, as well as Snyder’s Yale colleague and spouse, Marie Shore, the celebrated author of The Ukrainian Night, are leaving Yale for Canada with good reason.
Author Timothy Snyder speaks about Democracy and the Risk of Tyranny with Public Policy Forum.
Shared mutual concern
While the departure of a handful of prominent academics is hardly a trend, it raises questions about whether there will be an accelerated academic “brain drain”, or more American students in Canada.
As a Canadian, I would like to say America’s loss is our gain, and I wish these scholars well. I am also aware that narratives of flight to Canada as refuge have historically bolstered national myths while obscuring Canadian inequities. My hope is that Canadians will not observe the arrival of U.S. scholars with smugness, but instead with shared concern.
We should not be blind to this unique moment in which Canada is called to revisit why we care about Canada and keep watch on the rule of law. Yet, we must also recognize our own profound historical blind spots.
Too much cynicism might prevent us from acknowledging the importance of these three scholars’ decisions to leave their country and come to ours at this particular time in history. However, my hope is also that we are also inspired by their considerable truth-telling skills to demand Canada also do better.
Jeffrey B. Meyers does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Source: United States Department of Justice (National Center for Disaster Fraud)
MIAMI – Raisha Kelly, 44, of Loxahatchee, FL was sentenced to sixty months in prison followed by three years of supervised release and ordered to pay $443,895 in restitution by United States District Court Judge Federico A. Moreno. The sentence follows Kelly’s conviction for conspiracy to commit wire fraud and wire fraud.
Kelly recruited and conspired with multiple individuals to submit Payment Protection Program (PPP) loan applications that falsely and fraudulently misrepresented that the applicants had sole proprietorship businesses, and the amount of annual revenue received by these purported sole proprietorship businesses. In support of these applications on behalf of each individual, Kelly submitted falsified tax returns. Kelly orchestrated this scheme in return for a 25 percent kickback from the loan applicants. Kelly concealed her involvement in the scheme by creating a series of “dummy” email accounts for herself and each of the applicants—all to entirely disguise her own involvement in the false and fraudulent application. Kelly also applied for her own PPP loans in which she also falsely and fraudulently mispresented the amount of income her own business received. At trial, it was proven that the defendant made approximately $106,649 as a result of orchestrating this conspiracy involving thirteen individuals.
U.S. Attorney Hayden P. O’Byrne for the Southern District of Florida; Acting Inspector in Charge Steven L. Hodges of the U.S. Postal Inspection Service (USPIS), Miami Division; Special Agent in Charge Amaleka McCall-Brathwaite, U.S. Small Business Administration Office of Inspector General (SBA OIG), Eastern Region; and Special Agent in Charge Mathew Broadhurst of the U.S. Department of Labor Office of Inspector General (DOL-OIG), Southeast Region, made the announcement.
USPIS, SBA-OIG, and DOL-OIG investigated the case.
Assistant United States Attorneys Daniel Bernstein, Eduardo Gardea Jr., and Gabrielle Charest-Turken prosecuted it.
In March 2020, the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act was enacted. It was designed to provide emergency financial assistance to the millions of Americans suffering the economic effects caused by the COVID-19 pandemic. Among other sources of relief, the CARES Act authorized and provided funding to the SBA to provide Economic Injury Disaster Loans (“EIDLs”) to eligible small businesses, including sole proprietorships and independent contractors, experiencing substantial financial disruptions due to the COVID-19 pandemic to allow them to meet financial obligations and operating expenses that could otherwise have been met had the disaster not occurred. EIDL applications were submitted directly to the SBA via the SBA’s on-line application website, and the applications were processed and the loans funded for qualifying applicants directly by the SBA.
On May 17, 2021, the Attorney General established the COVID-19 Fraud Enforcement Task Force to marshal the resources of the Department of Justice in partnership with agencies across government to enhance efforts to combat and prevent pandemic-related fraud. The Task Force bolsters efforts to investigate and prosecute the most culpable domestic and international criminal actors and assists agencies tasked with administering relief programs to prevent fraud by, among other methods, augmenting and incorporating existing coordination mechanisms, identifying resources and techniques to uncover fraudulent actors and their schemes, and sharing and harnessing information and insights gained from prior enforcement efforts. For more information on the Department’s response to the pandemic, please visit https://www.justice.gov/coronavirus.
On September 15, 2022, the Attorney General selected the Southern District of Florida’s U.S. Attorney’s Office to head one of three national COVID-19 Fraud Strike Force Teams. The Department of Justice established the Strike Force to enhance existing efforts to combat and prevent COVID-19 related financial fraud. For more information on the department’s response to the pandemic, please click https://www.justice.gov/coronavirus.
Anyone with information about allegations of attempted fraud involving COVID-19 can report it by calling the Department of Justice’s National Center for Disaster Fraud (NCDF) Hotline at 866-720-5721 or via the NCDF Web Complaint Form at: https://www.justice.gov/disaster-fraud/ncdf-disaster-complaint-form.
Related court documents and information may be found on the website of the District Court for the Southern District of Florida at www.flsd.uscourts.gov or at http://pacer.flsd.uscourts.gov under case number 24-cr-20079.
Source: United States House of Representatives – Congressman Adrian Smith (R-NE)
Washington, DC — Reps. Adrian Smith (R-NE), Brad Schneider (D-IL), Diana Harshbarger (R-TN), and Doris Matsui (D-CA), introduced the Ensuring Community Access to Pharmacist Services Act. The members released the following statements:
“Giving seniors more options to meet their healthcare needs is a valuable way to improve outcomes for patients,” said Rep. Smith. “Pharmacists are trusted, key partners in seniors’ care, particularly in rural communities where health provider availability is limited. Allowing greater flexibility for treatment of common respiratory illnesses is a commonsense solution to increase access to care. I thank Reps. Schneider, Harshbarger, and Matsui for partnering with me on this important legislation.”
“Pharmacists have long played a crucial role delivering quality health care to Americans, including helping prevent the spread of infectious disease,” said Rep. Schneider. “We need to empower pharmacists to continue providing care to seniors and receiving reimbursement for services related to COVID-19, influenza, respiratory syncytial virus (RSV), and strep throat. I’m proud to work on this important initiative with my colleague on the Ways and Means Committee, Congressman Adrian Smith.”
“This bipartisan legislation will modernize Medicare and help ensure our seniors — especially those in rural and medically underserved communities — have timely access to healthcare from the most trusted health professionals in their communities,” said Rep. Harshbarger.
“Our pharmacies are directly in the heart of our communities, providing frontline care and services to those who need it most,” said Rep. Matsui. “Time and again, pharmacists have stepped up to meet public health threats and administer vaccines, tests, and other critical services that keep Americans healthy. That’s why we must make sure they have the federal support they need to continue this work. The Ensuring Community Access to Pharmacist Services Act would ensure that Medicare patients can continue to access these services well into the future.”
The Ensuring Community Access to Pharmacist Services Act would provide for Medicare coverage of pharmacist-administered tests for common respiratory illnesses, such as influenza, respiratory syncytial virus (RSV), strep throat, and COVID-19. It would also allow pharmacists to prescribe treatments for these illnesses when properly indicated. These flexibilities were initially provided during the COVID-19 Public Health Emergency (PHE) through various emergency waivers but have since lapsed. The Ensuring Community Access to Pharmacist Services Act would not preempt existing state scope of practice laws regarding the ability of pharmacists to legally perform these services.
The legislation is supported by the Future of Pharmacy Care Coalition. Coalition members include the American Pharmacists Association (APhA), American Society of Health-System Pharmacists (ASHP), Abbott, AmerisourceBergen, Cardinal Health, CVS Health, Good Neighbor Pharmacy, Health Mart, Kroger, McKesson, Medicine Shoppe, the National Association of Chain Drug Stores (NACDS), Walgreens, and Walmart. The coalition released the following statement on the legislation:
“The Future of Pharmacy Care Coalition commends Rep. Adrian Smith (R-NE), Rep. Brad Schneider (D-IL), Rep. Diana Harshbarger (R-TN), and Rep. Doris Matsui (D-CA) for introducing the Ensuring Community Access to Pharmacist Services Act (ECAPS) to ensure seniors, including those living in rural areas and vulnerable communities, can turn to their local pharmacists for testing and treatment services that can protect them from certain common respiratory conditions. Congress must move quickly and provide seniors with Medicare coverage in states where pharmacists can offer testing and treatment services for conditions that, although common, can quickly become life-threatening if not properly managed.”
Source: United States Senator for Washington State Patty Murray
ICYMI: At Hearing, Senator Murray Slams Trump Administration for Threatening Biomedical Research and Jeopardizing Americans’ Health
NIH Investments support more than $3 billion in economic activity across Washington State and more than 12,000 jobs – MORE HERE
***AUDIO HERE; PHOTOS and B-ROLL HERE***
Seattle, WA— Today, U.S. Senator Patty Murray (D-WA), Vice Chair of the Senate Appropriations Committee, held a roundtable discussion in Seattle highlighting why the investments the federal government makes in biomedical research are so vital, what’s at stake for patients and families as Trump takes a wrecking ball to this research, and why Congress must forcefully push back. Murray was joined by Seattle area leaders in biomedical research of national renown, patients who have benefitted directly from NIH research, and early career researchers who can speak directly to how Trump’s cuts and chaos are jeopardizing the future of biomedical research in America.
During the roundtable, Senator Murray was joined by Dr. Jeff Sperring, Seattle Children’s Chief Executive Officer; Dr. Vittorio Gallo, Seattle Children’s Chief Scientific Officer; Dr. Mary-Claire King, American Cancer Society Professor of Medicine and Genome Sciences, UW School of Medicine; Dr. Jane Hoyt Buckner, M.D., President of Benaroya Research Institute; Kristin Weinstein, PhD candidate at UW School of Medicine; and Alisa Vitello along with her daughter, Olivia Vitello, who benefitted from medication developed through an NIH clinical trial.
President Trump and his administration has systematically undermined NIH and the research it funds, which is having devastating impacts on biomedical research, innovation, and ultimately, the lives of millions of patients and families. The Trump administration’s actions are delaying funding and stalling research for lifesaving treatments and cures, weakening our biomedical workforce, cancelling vital ongoing studies and trials, and threatening to undo decades of hard-won progress.
“Medical research is an economic powerhouse—it supports millions of jobs across the country, especially here in Washington state, and generates billions in economic activity. NIH funding is the cornerstone of our medical research enterprise, while medical research accounts for less than 1 percent of the federal budget, NIH has contributed to over 99 percent of drugs approved by FDA in recent years,” said Senator Murray. “But the real impact isn’t economic, it isn’t jobs, it isn’t awards, it is miracles that give people hope and more time with loved ones. That could mean a new vaccine to protect us from a disease. It could mean new treatment that saves lives. Or a breakthrough discovery that revolutionizes care and research, like Dr. King’s work showing a gene tied to breast cancer.”
“That is all invaluable—but with President Trump—it is all on the chopping block,” continued Senator Murray. “He has already axed 800 grants, over a billion dollars in research for HIV prevention, breast cancer, pregnancy, diabetes, Alzheimer’s, and more. He has also blocked $2 billion in grant funding from going out to universities and research institutions across the country.He slapped a $1 limit on NIH researchers’ payment cards—meaning labs can’t get gloves, pipettes, and vials—the basics they need to keep research going.He wants to massively cut funding for basic costs that keep labs running.And Trump is calling for at least an $18 billion cut to NIH funding. And it’s not just funding Trump has cut—it’s the workforce. Trump has pushed out nearly 5,000 people at NIH and counting.He is slashing grants to support early educators. And he is pushing out and scaring away international students. We are seeing canceled trials and delayed research. We must keep up the public pressure. People need to know what is happening. They need to know what is at stake.”
Murray’s roundtable discussion follows a bipartisan Senate Appropriations Committee hearing she co-led this week, where she invited testimony from Washington state mom and patient advocate, Emily Stenson, whose daughter Charlie was diagnosed with stage 4 cancer at just three years old but who, thanks to a National Cancer Institute clinical trial at Seattle Children’s Hospital, has been cancer free since December 2024.
“Children are our future, and we drive advances—like improving survival rates for children with brain tumors, developing new therapies for rare diseases, and transforming care for kids with complex behavioral health needs—through research,” said Dr. Vittorio Gallo, Chief Scientific Officer at Seattle Children’s. “Without sustained NIH investment, nearly 200 clinical trials at Seattle Children’s could be delayed or paused. Funding is critical for us to deliver on our mission to provide hope, care and cures.”
“I wanted to first tell you what’s happened to me in consequence of this craziness. I am now owed—4 months later—$1.8 million of a noncompetitive renewal on a project that has been approved at all scientific levels. The Notice of Grant Award has been signed. It was to begin last January 1. It has simply not been sent. It’s not canceled. It just hasn’t come. Somehow it is frozen. No reason has been given. There is no DEI component, it’s only sequencing of DNA…There are probably thousands more like me. That estimate of the of the total cost—the total deficit into those 800 [grants]—I think is only a very small fraction of the actual amount of money that we need as researchers, that has been guaranteed for us. They will need to burn this money if they don’t send it. This money is allocated to the University of Washington. They can’t use it for anything else. They might as well take out the bills and just burn them. In addition to the research itself, it supports 4 young investigators. We’re now 4 months in with their having no salaries from that grant. I’m using my own salary, I’m using gifts that I’ve been accumulating for 50 years to pay them. So far so good, but we’ll run out pretty quickly. Grants like this need to be dislodged from the iceberg in which they are now frozen,” said Dr. Mary-Claire King, American Cancer Society Professor of Medicine and Genome Sciences at UW School of Medicine. Dr. King was the first person to show that breast cancer can be inherited due to mutations in the gene she called BRCA1. Dr. King also shared the story of a woman who participated in one of her projects, “She said, ‘My mother died of breast cancer when I was 14. She missed my high school graduation. She missed the decisions about my going to college. She missed my college graduation. She missed my marriage. She missed the birth of her granddaughter. When I learned that it was possible to have testing to learn if I was predisposed to breast cancer, I was tested right away. I have a mutation in BRCA 1, that surely is what killed her. As soon as I was old enough, I had the same surgery that Angelina Jolie had, and I am now fine. My daughter graduates from high school this June, and I will be there. Just thought, you want to know.’ We owe it to her to bring the NIH back to health. So, thanks very much for what you’re doing.”
“We study immune diseases, particularly autoimmune diseases and allergies. [Autoimmune diseases] affect 25 to 50 million Americans. [Allergies] affect 25% of Americans, in fact two kids in every classroom. And we’re funded 70% by the National Institute of Health, and that work you know, that supports fundamentally understanding these diseases and also clinical trials to test the next new therapy. As well as ways to prevent ever getting a disease like type one diabetes. We want kids never to have to face using insulin every day…I do this because I’m also a physician and a rheumatologist, so I care for people with arthritis, and I’ve been doing that for 30 years. And for the first 10 years of my career, we didn’t have much for my patients and our waiting rooms were filled with wheelchairs. You had to reorganize furniture for our patients. And then drugs called biologics were discovered—in fact, one of the first ones came from the Seattle area—and literally, patients got out of wheelchairs and walked in a week. That research started 30 years before, and that was funded by NIH research, and it would have actually never become a product if those studies hadn’t been done. Today, I still see patients with rheumatoid arthritis, and they’re doing so much better. We don’t have wheelchairs in our waiting rooms anymore,” said Dr. Jane Hoyt Buckner, M.D., President of Benaroya Research Institute. “You may not know you need the cure that is going to be discovered through this research, but in 10 years you may, or your family member may, and by not funding the NIH, some of those cures won’t be there in 10 years. And I also think some of our young people who are trying to choose a career in science are going to be turned away. And it’s only been 100 days, but the chaos that’s been created in that 100 days is already impacting people. We see it now, people choosing not to go to graduate school, people choosing alternative careers, scientists thinking I should move out of the United States. And I can also say I’m fortunate to work very closely with many people at the NIH, particularly on clinical trials trying to cure diseases of the immune system, and they are struggling to continue to do that work. They’re understaffed, they aren’t able to get things out, and they don’t know what’s going to happen next. I know they’re really looking to Congress to help us find a way out of this.”
“Unstable funding from the NIH for biomedical research will have long-lasting, devastating impacts. Early career scientists like myself will be forced to go abroad to continue our training, patients will unnecessarily suffer or die from the diseases that this research could cure, and the United States will cede its position as the global leader in biomedical research,” said Kristin Weinstein, PhD candidate at UW School of Medicine. “I am holding onto the hope that the American public and its leadership will recognize the vital importance of biomedical research, reinstate federal funding for this work, and support our hard-working scientists. At the end of the day, I just want to be in the lab doing what I love most: Making scientific discoveries that will lead to cures for diseases like cancer and autoimmunity.”
Trump and Elon Musk’s DOGE have terminated nearly 800 NIH grants across the country, cutting off more than $1.1 billion in essential research and trials and continue to terminate more grants every week. So far this year, he has slow walked roughly $2 billion in vital NIH funding that should be going out the door to fund the research that might discover the next treatment or cure that will change—or save—a patient’s life.
These grant terminations are a result of the Trump Administration’s Executive Orders against whatever it deems DEI and targeted attacks on specific academic research institutions, which are disrupting landmark diabetes research, targeting promising mRNA vaccines, and spreading vaccine hesitancy amidst a measles outbreak. A full list of HHS grant terminations can be found here. To date, NIH grant terminations include:
Grants that fund research on HIV prevention, breast cancer, uterine cancer, stroke risk, cardiac health, suicide prevention, smoking cessation, eating disorders, COVID-19, pain, alcohol use disorder, depression, violence prevention in children, pregnancy health disparities, diabetes and obesity, and Alzheimer’s disease;
More than 270 grants totaling at least $125 million for research focused on improving the health of LGBTQ Americans;
Stop work orders for all NIH training grants that support diverse undergraduate and graduate students and early career scientists, including the Undergraduate Research Training Initiative for Student Enhancement (U-RISE), the Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC), and F31 Diversity training programs.
The Trump Administration’s actions, including directly terminating early career training programs funded by NIH, are devastating the pipeline of early career researchers and threatening the next generation of breakthroughs, treatments, and cures. On March 31st, an open letter signed by nearly 2,000 of the country’s top scientists including a number of Nobel Prize winners urged the Administration to stop its wholesale assault on U.S. science, which is decimating research, driving scientists to leave the country and putting America at risk of losing a generation of scientists.
Trump has illegally sought to cut billions in funding for universities to conduct this vital research by illegally capping the indirect cost rate in direct violation of bipartisan appropriations law—a federal judge has issued a nationwide injunction against the cap on indirect costs, but the Trump administration is appealing the ruling. The uncertainty around NIH’s indirect cost rate policy has led universities and research institutions around the country to implement hiring freezes, rescind graduate student admissions offers, and shutter entire graduate school programs.
President Trump has pushed out nearly 5,000 NIH employees and 4,000 FDA employees—decimating the very work responsible for discovering lifechanging treatments and cures and ensuring they can safely get to market. He also reportedly plans to propose to nearly halve NIH’s budget.
Senator Murray has been leading the charge against the Trump administration’s efforts to gut lifesaving research at NIH and pushed out nearly 5,000 NIH skilled scientists, grants administrators, and other employees at the agency. When the Trump administration attempted to illegally cap indirect cost rates at 15 percent, Senator Murray immediately and forcefully condemned the move, led the entire Senate Democratic caucus in a letter decrying the proposed change, and introduced amendments to Senate Republicans’ budget resolution to reverse it, which Republicans blocked.
As a longtime appropriator and former Chair of the Senate HELP Committee, Murray has led Congressional efforts to boost biomedical research. Previously, over her years as Chair of the Labor-HHS Appropriations Subcommittee, Senator Murray secured billions of dollars in increases for biomedical research at NIH, and during her time as Chair of the HELP Committee she established the new ARPA-H research agency as part of her PREVENT Pandemics Act to advance some of the most cutting-edge research in the field. Senator Murray was also the lead Democratic negotiator of the bipartisan 21st Century Cures Act, which delivered a major federal investment to boost NIH research, among many other investments.
India all set to emerge as Meetings, Incentives, Conferences, and Exhibitions (MICE) capital of the world- Gajendra Singh Shekhawat About 700 leading industry players and decision maker from the exhibition sector attend
Posted On: 02 MAY 2025 4:19PM by PIB Delhi
With the construction of the state-of-the art exhibition and conference complexes in the country, India is all set to become MICE ((Meetings, Incentives, Conferences, and Exhibitions) capital of the world.
“The new segments of tourism are getting developed, in which MICE tourism is the most important and is the fastest growing segment in the country. The exhibition and conference infrastructure we see across the nation including Mumbai, Delhi, Hyderabad, Bangalore, Jaipur and even small cities post G20 meet indicates that India is standing at the threshold of strong possibilities for this sector,” said Gajendra Singh Shekhawat, Union minister of Culture and Tourism, while inaugurating a Two-day Seminar on India: The land of Exponential Growth organised by the Indian Exhibition Industry Association (IEIA) , the apex national body of exhibition industry in the country.
“The government and the private exhibition industry has to work together to make India a centre of MICE tourism. Several events which are happening globally can be calendarized and brought here in India. Besides being a destination India, the country is also becoming a big Exhibition and conference hub with planned expansion in road, aviation and railway sectors along with expansion of the conference and exhibition sector, the country has a great future for economic growth,” Shekhawat said.
“After 2014, India has shown a tremendous growth curve in infrastructure given the boom in infrastructure, be it the construction of roads over 1,50,000 km, new railway stations, semi high-speed trains, inland waterways and more than 150 operational airports. All of these have contributed to India’s prowess with regards to the MICE events (Meetings, Incentives, Conferences, and Exhibitions). The confidence also built following India’s hosting of G20 nations, the entire world is looking at India in awe and curiosity. In times to come, India will emerge as the MICE capital of the world.” Said Mr Shekhawat.
“The IEIA Open Seminar and Exhibition Services Expo is the annual international conclave of the Indian Exhibition Industry attended by the captains of the industry from all regions of the country and overseas. The event acts as one of its kind meaningful platforms for business networking, knowledge exchange, and discussions on the emerging trends shaping our industry’s future.” Said Mr Sooraj Dhawan, President. Indian Exhibition Industry Association (IEIA).
“The 14th edition, the IEIA Open Seminar is expected to attract over 700 leading industry players at decision maker levels including leading Exhibition/ Event Organisers, heads of various trade bodies, sectoral associations and key govt. bodies. India is the fastest growing exhibition market in the world and has grown at 40% post Covid. The Exhibition Industry’s contribution to the Indian economy is Rs. 50,000 crores. Business generated through exhibitions is Rs. 300,000 crores.” Said Mr Dhawan.
“The Meetings, Incentives, Conferences, and Exhibitions (MICE). refers to a specialized segment of the tourism and hospitality industry focused on organizing and hosting business events. We urge the govt to announce October 1 as the National MICE Day as further boosting the morale of the industry.” Said Mr Dhawan.
MICE is also known as the event industry. Over the past decades, the MICE industry has been recognized as a significant market segment and an important contributor to national economies. It not only gives a boost to the economy in the form of income generation, but creates huge employment opportunities in related hospitality services providing sectors like accommodation, food and beverage, convention services, transportation, tourism and entertainment.
Those present on the occasion included Mr Premjeet Lal ED, ITPO, Mr Rakesh Kumar, MD, India Expo mart, Mr Jagdish Patanakar Hon Secretary IEIA, and Mr Ravinder Sethi, vice president, IEIA
Source: United States House of Representatives – Congresswoman Dina Titus (1st District of Nevada)
Congresswoman Dina Titus reiterated her warning about a budget crisis in Nevada after the Nevada Economic Forum today approved a forecast predicting a slowdown in revenues to fund vital state services.
“The combination of the Trump tariffs and the DOGE cuts to vital programs like Medicaid are putting Nevadans at risk,” Congresswoman Titus said. “We are being asked to fill the gaps left by federal cuts to services while the Trump tariffs are damaging our economy and shrinking state revenues.”
The Nevada Economic Forum, which sets revenue projections for the Nevada Legislature to use in finalizing a 2025-27 biennial budget, approved a forecast projecting about $190 million less in revenues from major taxes than it projected in December 2024.
“That means there will be even less money for education, social services, infrastructure ,and environmental protection,” Congresswoman Titus said. “It is more important than ever that Nevadans call on the Trump administration to reverse course on tariffs and oppose the draconian budget cuts by DOGE and the Republican Congress.”
Congresswoman Titus recently addressed the Nevada Legislature and warned legislators about a “tsunami” of federal cuts coming to Nevada, which relies on federal funding for 27.7 percent of its state budget. In particular, she noted the state may lose $3 billion in federal funding for Medicaid, which provides health care coverage for 812,000 Nevadans. Congresswoman Titus also noted the loss of federal funds to support Nevada schools and nutrition programs.
She said today that the Trump tariffs are already taking a toll on the state’s economy, citing a report this week that visitation to Southern Nevada in March plunged 7.8 percent from a year ago, one of the steepest year-over-year drops since the coronavirus pandemic.
“Nevada is often the first state to suffer from economic downturns because of our reliance on tourism,” Congresswoman Titus said. “We must oppose federal policies that will mean job losses and cuts to services when Nevadans need them most. The future of our state is at stake.”
On May 10 and 12, 2025, the College of Agriculture, Health and Natural Resources (CAHNR) and the Ratcliffe Hicks School of Agriculture will recognize graduates as they meet a major academic milestone.
Learn about a few of the nearly 600 stellar students who will soon become CAHNR alumni.
Bendy Al Zaatini, Allied Health Sciences
Hometown: Waterbury, CT
Why UConn? Throughout the chaos of the pandemic, I was positive that staying at home while simultaneously building my community at UConn Waterbury would be the right way to start my journey as an undergraduate student at the prestigious school. I was surprised by the number of resources that are available to students. There is always help when needed and many different pathways to achieve success.
Why your major? I am an Allied Health Sciences major, and I was drawn to it because of the different career opportunities that fall under this major. My plan after graduation is to receive my second bachelor’s degree through CEIN, the accelerated nursing program with UConn, starting January 2026.
Advice for incoming students? Stay busy, make your presence known, and make sure that everything you are involved in benefits you in different ways. Throughout your many involvements, never forget that you are a student first and prioritize your grades above all else.
Benjamin Angus, Agricultural and Resource Economics
Hometown: Avon, CT
WhyUConn? I have been a UConn fan my entire life, so for me it was a no brainer. Coming to Gampel as a kid or tailgating at Rentschler, UConn sports for me wasn’t a hobby, it was a lifestyle.
Why your major? I am a double major in Environmental Science and Natural Resource Economics. I am eager to join the fight against climate change and am looking forward to wherever that takes me. It is the most pressing issue of our time. After graduation, I am exercising my Covid year and coming back to UConn to get my Masters in Applied Resource Economics. After that, who knows? Wherever the wind takes me.
Advice for incoming students? When you sit down in class on the first day, talk to the person next to you. Learn their name, get their number, ask them their life story – just put yourself out there and I promise you will meet some incredible human beings. Also, bundle up on a clear winter night and walk to the top of Horsebarn Hill. No one ever looks at the stars in the winter, they are breathtaking.
Matt Antunes, Plant Science and Landscape Architecture
Hometown: Smithfield, RI
WhyUConn? UConn was a top ranked school in my choices for college, and I felt like I would get the best education for my major. I felt at home in my time at UConn with the friends and connections I made throughout my four years here.
Why your major? Plant Science (Sustainable Plant and Soil Systems) – with a turfgrass concentration. I always had a love for turf from a young age. Beginning with just mowing my home lawn as a teenager to eventually building a small putting green, I found I was always around turfgrass systems in my summers. I plan on continuing my education here as a graduate student studying turfgrass pathology, and I plan on working in the golf course industry as an assistant superintendent and hopefully a superintendent down the road.
Advice for incoming students? Go to a UConn sporting event (especially basketball even if you’re not into it). The energy and atmosphere are unmatched to any other sporting event I’ve been to in my lifetime.
Jillian Bowen, Pathobiology and Veterinary Science
Hometown: Trumbull, CT
WhyUConn? The academics were the main draw for me. As an R1 institution, I knew that UConn had a lot of research opportunities, and that really drew me in.
Why your major? My major is Pathobiology, or disease biology. I attended an agricultural high school and was a member of Future Farmers of America, so I already had an interest in animal science, but the pandemic was definitely a big factor in stimulating my interest in infectious diseases. Pathobiology is a perfect combination of those interests! After graduation, I am planning to attend UConn’s Master of Public Health program with a concentration in epidemiology.
Advice for incoming students? Variety is the spice of life, so don’t be afraid to try something completely different – learn how to breakdance! Join an improv group! Start a book club! The world is your oyster.
John-Henry Burke, Natural Resources and the Environment
Hometown: Suffield, CT
Why UConn? I chose UConn because I thought it offered the best ‘bang for my buck.’ You get an incredibly large institution with a large number of resources and a diverse array of opportunities for a price that is much more affordable than other schools.
Why your major? I’m an Environmental Science major with a concentration in Sustainable Systems and a minor in Political Science and a minor in Environmental Economics and Policy. I was drawn to environmental science after taking a class in high school where I learned about climate change, plastic pollution, species extinction, and other threats facing our planet. I’m going to law school in the fall, and I would like to ultimately go into environmental law to advance environmental policy and protect natural areas.
Top UConn memories? One of the best parts of my UConn experience has been playing in the UConn Marching Band, where I served as Vice President. I’ve met so many amazing people through the band and accomplished a level of musicality I would’ve never imagined possible. Some notable UCMB performances were playing at a New England Patriots game and two Bowl games (Fenway and Myrtle Beach)!
Christian Carmona, Plant Science and Landscape Architecture
Hometown: Stamford, CT
WhyUConn? I chose UConn because it helped me the most financially and it was not as far away from my house as others were.
Why your major? My major is Landscape Architecture, and what drew me to it was that it was a form of architecture I had never heard of before. I was eager to try it out, and it gave me the opportunity to be creative and design spaces for communities. I hope to continue my education and pursue a master’s in architecture.
Advice for incoming students? Be open minded and ready to learn. You are here for a reason so stay focused on your goals and do not take anything for granted.
Laura Centanni, Animal Science
Hometown: Haworth, NJ
WhyUConn? I was leaning towards UConn due to the diversity of species in our barns on campus; however, what tipped the scales in the end was the mascot!
Why your major? My major is Animal science. I have had a passion for animals and service for as long as I can remember, and I am pursuing my passion of becoming a veterinarian through animal science here at UConn. I have already received my first few acceptances to vet school! Wherever I choose, I know that UConn prepared me well.
Advice for incoming students? Expand your comfort zone. Let it get so big that nothing is outside of it. UConn is one of the safest environments to explore that you will ever have, so take advantage of it!
Jessica Harris, Allied Health Sciences
Hometown: Mansfield, MA
WhyUConn? When it was time for me to look at colleges, I was excited to apply to UConn as is but I also discovered that CAHNR offered the major I was interested in, Allied Health Sciences, as part of the New England Regional Tuition Program. This made UConn such an easy choice for me because of its well-known academic excellence and affordability as an out of state school.
Why your major? I applied into UConn as an AHS major, because it would allow me to do my prerequisite courses to apply to physical therapy school, but I soon learned that it was not the right path for me. Luckily, AHS is such an adaptable major, intended to cater to your career interests, that I was able to stay on track despite changing paths, and ended up finding exactly what I wanted to do: UConn’s CEIN program.
Top UConn memories? Going to the UConn Dairy Bar, and 2023 when we won the Men’s National Basketball Championship for the first time in a while.
Sungwan Kim, Kinesiology
Hometown: Gyeongju, Republic of Korea
WhyUConn?UConn was my one and only choice because the research topics of my Ph.D. advisor, Dr. Neal Glaviano, perfectly align with my interests. Additionally, the collaborative research culture at UConn offers a unique opportunity to work with leading experts and engage in interdisciplinary projects, further enhancing my professional development.
Why your major? I am completing my PhD in Exercise Science. Working clinically as a certified athletic trainer, I witnessed firsthand the significant impact that orthopedic conditions have on individuals’ lives. This experience motivated me to investigate how musculoskeletal injuries or pain affect physical and psychological well-being and to explore optimal treatment strategies for rehabilitation and recovery. After graduation, I will start my postdoctoral research fellowship at Boston Children’s Hospital and Harvard Medical School.
Top UConn memories? One thing everyone should do during their time at UConn is take advantage of the Recreation Center. Whether it’s lifting weights, playing sports, or just taking a break after a long day, it’s a great place to stay active and recharge!
Gramos Medjolli, Kinesiology
Hometown: Korça, Albania
WhyUConn? I had heard a lot of great things about UConn from a few people I knew, and I learned what an excellent institution it is. In fact, UConn was the only university I applied to—it was UConn or nothing! I thought to myself, if it’s meant to be, it will be. And it was! At the time, I was living in Germany and already practicing as a physical therapist.
Why your major? My grandpa always said, “The flowing water always stays fresh.” That’s why I decided to pursue the Doctor of Physical Therapy program at UConn, even after already being a licensed PT in Albania and Germany. I wanted to be the best version of myself in my profession because I love what I do. I truly believe physical therapy is one of the best jobs someone can have. If you’re not making someone else’s life better, then you’re wasting your time. I also want to advocate for the field of physical therapy and create things that will benefit the community.
Advice for incoming students? Don’t stress too much in advance. He who suffers before it’s necessary will suffer more than necessary. You won’t remember how many hours you studied, but you will remember the beautiful moments and adventures you experienced.
Yasmin Rosewell, Agricultural and Resource Economics
Hometown: Las Vegas, NV
WhyUConn? I chose UConn because of its diverse and upbeat environment. The student body is heavily involved in the sports teams, clubs, and educational opportunities the school has to offer.
Why your major? Economics of Sustainable Development and Management. I was drawn to this because I enjoyed the business aspects of the major, but the department was so involved in the students’ learning and offered great connections and opportunities to learn through different outlets. As an athlete, all of my professors within the department were extremely supportive and accommodating of my absences during the season, and that helped me succeed and learn the material without being overly stressed. After graduation, I plan to travel and then move to New York City and pursue a career in logistics.
Advice for incoming students? Everyone on this campus is truly rooting for each other. The sense of comradery is one of a kind and the students and staff of UConn are encouraging, inclusive, and collaborative. So be bold. Don’t be afraid to be amazing. There is a place here for everyone and you will find yours. There are always people behind you and in your corner.
Sydney Seldon, Natural Resources and the Environment
Hometown: Harker Heights, TX
WhyUConn? I originally came to UConn to play on one of the athletic teams here but when that didn’t work out, I was launched into a time of self-discovery, which unleashed a deeper purpose and passion for spiritual formation and sustainability (both social and environmental).
Why your major? My major is unique – Environmental Science and an Individualized Major in Sustainable Communities with a Minor in Sustainable Community Food Systems. After graduation, I’ll be joining staff with the Navigators, an international, interdenominational Christian ministry, and walking alongside students as they explore faith and spirituality.
Advice for incoming students? Be courageous. College brings with it a host of new experiences and opportunities to grow so surrender to it. Allow yourself to be challenged and molded into not only a committed learner, but also a committed individual. Allow your conceptions about the world and yourself to be challenged. Find people who gracefully love you and push you to be the best version of yourself, so that out of that, you can contribute to being a positive influence in the world around you.
Noah Sneed, Pathobiology and Veterinary Science, Animal Science
Hometown: Natick, MA
WhyUConn? I chose UConn because of the opportunities for hands-on learning, as well as their extensive commitment to academia and research as an R1 university.
Why your major? I came into college as an animal science major who was planning on going to veterinary school. I was drawn to it because I have always loved animals, and I was so excited to be able to get hands-on experience working with horses, pigs, sheep, chickens, and of course cows. I was drawn to pathobiology because I realized that further than just administering vaccinations, I was interested in how they worked and the process to make them. I was able to join a pathology research lab on campus, and it has been such an enriching experience. After graduation, I am taking two gap years before medical school. I will be working full time as an EMT in the Boston area, as well as completing a Post-Baccalaureate program at the Tufts Graduate School of Biomedical Sciences.
Advice for incoming students? Everyone should go to a men’s and women’s basketball game at Gampel Pavilion and sit in the student section. I have never felt so much pride for my school before; it is truly an amazing experience.
Mingda Sun, Nutritional Sciences
Hometown: Farmington, CT
WhyUConn? I chose UConn because I am from Connecticut, and did not want to go to school too far away from home. I also chose UConn because it has a strong nutrition and pre-medical program, which were areas of study I wanted to pursue. Moreover, UConn is a large school with students of many different backgrounds, and I felt like it was a place where I could belong and find a community of friends.
Why your major? I am a nutrition major with a minor in Spanish. I am passionate about how nutrition relates to health and the human body and have worked in numerous community health and public health initiatives as an undergraduate that are related to nutrition and disease prevention. Learning different languages is something I enjoy and believe is an important skill for connecting with patients and populations as a future health care professional. After graduation, I plan to attend medical school and become a doctor!
Advice for incoming students? Do not be afraid to reach out for support, mentorship, or guidance when you need it. If you have an idea or a passion that you want to pursue, there are faculty and students at UConn who are willing to help you. Don’t be afraid to take the initiative for your own learning!
Matt Syrotiak, Animal Science
Hometown: Bethlehem, CT
WhyUConn? I spent a great deal of time here at UConn through 4-H activities and high school FFA competitions. It’s safe to say that the Storrs campus was familiar to me from early on, despite my family having never been and never attending college themselves. While it was the campus and familiarity that drew me to UConn, it was the community of students, faculty, and staff that made me stay.
Why your major? My major is Animal Science, and I was drawn to it thanks to my involvement with the UConn Extension 4-H program where I worked on my dairy goat project. Through working with my goats, I gained a greater interest in the field, and it was reinforced by my time in agriscience classes throughout high school. UConn was the perfect fit to continue my work in animal science thanks to the proximity of the barns on campus and emphasis of hands-on class work. After graduation, I’ll serve as State 4-H Program Coordinator with UConn Extension, and create meaningful connections for 4-H youth, volunteers, and educators to increase the reach of the college and its community.
Advice for incoming students? The connections that you gain through being a part of the UConn community are critical to future success whether its classmates, educators, or alumni. You never know when those people will make a new appearance in your life.
Jonathan Vasquez Garcia, Nutritional Sciences
Hometown: Willimantic, CT
WhyUConn? Ever since I was little, I was always part of various programs associated with UConn, and when I came to campus, I felt that this school was my calling.
Why your major? I originally wanted to become a nurse. However, during my fall semester of sophomore year, I took my first nutrition class, where I gained valuable insight into the role of a registered dietitian. Ultimately, I changed my major to pursue a path aligned with my newfound passion for nutrition and sought out experiences that would deepen my understanding of the field. After graduation, I plan to pursue a master’s in clinical nutrition and complete my dietetic internship to become a registered dietitian. Eventually, I plan to work in a clinical setting to further gain foundational knowledge.
Advice for incoming students? My advice is to have fun and take advantage of all the resources UConn has to offer. And you should diversify your social network; you never know who you will meet.
Source: United Kingdom – Executive Government & Departments
Speech
Dame Angela McLean’s speech at the Royal Institution
This is a draft text of the speech ‘Discourse: The future of engineering biology’ delivered by Government Chief Scientific Adviser Professor Dame Angela McLean at The Royal Institution on 25 April 2025.
I want to start by asking you all to think about how you got here tonight.
I don’t mean in some philosophical sense; that kind of question is better left to other speakers. I mean literally: how did you make your way, here, to the Royal Institution?
If you’re anything like me, you relied on Google Maps to show you the way (although I may be obliged to say “Other providers are available”). Perhaps you also used your phone to pay for the bus or Tube.
If you’re joining us online – hello to you all! – you’ll be watching on a phone, tablet or laptop. So, one way or another, most of us made it here thanks to 1 of these devices.
Now I want you to think about the battery in your phone. Chances are it’s a lithium-ion battery. And if you came in an electric car or bus, you would also have depended on a lithium-ion battery.
The advantage of lithium-ion batteries compared to traditional alkaline batteries – the kind you may still put in the back of your TV remote – is that they can provide more energy and are rechargeable. People old enough to have depended entirely on alkaline batteries for many more devices besides the TV remote will remember the frustration when they ran out of power – and trying to cobble together another set of batteries to get them working again. Our phones may go dead, but it’s simple and convenient to recharge them.
But there is a downside, namely all the metals that go into making these modern batteries and electrical products, including lithium, cobalt and other rare earth elements.
Getting hold of these metals is hard. Most are currently extracted and purified from compounds in rocks, a process which can be very energy-intensive as well as very polluting.
Recycling and reusing these same metals is also hard.
This is the periodic table of the elements created by Dmitri Mendeleev, first published in 1869 and subsequently presented right here at the Royal Institution some 20 years later.
How many elements do you think are used in electronic products?
Electronic products can contain up to 60 different elements – around 52 of them metals (those are the elements highlighted in blue on the slide) – and we currently rely on inefficient and environmentally damaging methods to isolate and recycle individual metals.
Indeed, many electronic items cannot be recycled. They simply go to landfill. This is already a serious issue and it’s 1 that will only get worse as global demand for electronics increases.
Well, what if I told you that researchers here in the UK have identified naturally occurring bacteria, which have the ability to extract and recycle metals from this sort of waste?
Hats off to anyone in the audience familiar with the strain of bacteria called Shewanella oneidensis MR-1, which can remove manganese from lithium-ion batteries. Or the bacteria Desulfovibrio alaskensis, which is capable of precipitating cobalt out from a mixture of the different metals and chemicals in lithium-ion batteries.
I’m only aware of these bacteria thanks to amazing research taking place in the UK, including by Louise Horsfall’s group at the University of Edinburgh. Louise’s team have been collaborating with researchers from across the country as part of the ReLib project, which stands for the reuse and recycling of lithium-ion batteries.
Actually, 1 of the funders for this project is the Faraday Institution, the UK’s flagship battery research programme named for the great Michael Faraday whose desk is in front of me.
On his desk I have a few items to use to help explain battery recycling.
Louise’s team have primarily been focused on recycling metals from large lithium-ion batteries used in electric vehicles. However, they can be pretty large – too large for me to bring here tonight. Nevertheless, many of you will know what a lithium-ion battery looks like from your phone – and the science behind how we can recycle these batteries is no different.
Once lithium-ion batteries reach the end of their life they can be disassembled and shredded using mechanical methods to produce this. In this case, the shredded material has come from part of the battery called the cathode, which contains lots of the metals we want to recycle.
Once we’ve dissolved this shredded material using chemical or biological methods, we get this solution here… called metal leachate. This contains the useful metals we’re interested in and it’s at this point that we introduce the bacteria I mentioned earlier.
The bacteria collect and excrete specific metals as tiny nanoparticles which we can recover to give us something like this… which is manganese that Louise’s team has produced in the way I’ve just described from this exact process! We can then use this manganese to build new batteries or other devices.
You might be wondering what do we do with what’s left behind in the leachate solution. Well, after the bacteria have done their work we are left with this biobrine which is rich in lithium – and resembles what you might find in lithium deposits in South America. This too can be used to make new batteries.
And I’m not just talking about using a few types of microorganism to improve the extraction and recycling of 1 or 2 metals. There appear to be lots of different microbes out there capable of extracting different metals. Indeed, it’s possible that the bacteria have evolved this capability in a way that detoxifies their own environment, collecting up and excreting harmful metals and so not being poisoned.
So if we use combinations of these bacteria and we tweak the characteristics of these strains, we can increase the efficiency with which metals are purified and recycled from waste.
That word tweaking is important and it doesn’t do justice to the science involved. What we’re really talking about is engineering existing microbes to extract and recycle metals.
Extracting metals from the ground is a hugely expensive and damaging process. It looks rather like this:
What you can see on the bottom part of this slide is an open cast manganese mine.
And once we’re finished with products needing such metals, we throw them away. The top part of this slide shows a landfill site after a fire. There have been reports of lithium-ion batteries causing fires at landfill sites across the world.
With engineering biology, we only need to remove metals from the ground once; thereafter they can become part of a genuine circular economy through continual re-use.
We use physics, chemistry and engineering to get them out of the ground but then we can and should use biology and engineering to keep recycling them.
And this is just 1 example of what is within our grasp thanks to the power and potential of the scientific field called engineering biology.
I’m speaking about engineering biology this evening because I believe it could be the most significant branch of science for decades to come.
I want to explain why I think that’s the case – and to share my excitement about this field for 2 main reasons.
The first is that the science and engineering involved in this field is, frankly, beautiful.
The second – and more important – reason is that both current and future applications will make a huge difference to the everyday lives of people in the UK and across the world.
I’m here to try to convince you of both these things, but if I can convince you of only 1, I want it to be the latter.
I’m really keen for people to recognise that the scientists and engineers in this field are working to produce solutions that most, if not all, of us can agree are necessary… urgently necessary even.
To kick off, I ought to say that – as Government Chief Scientific Adviser – my role is to advise the Prime Minister and the Government on all matters related to science, technology and engineering.
The job – and the advice – is a mixture of proactive and reactive work. It covers everything from providing scientific and technical advice during a national emergency to explaining the risks and opportunities around emerging technologies like artificial intelligence and engineering biology.
Now, in getting to grips with the promise of engineering biology, I did have a little bit of a head start.
I am a mathematical biologist by background. My own research focused on using mathematical models to improve our understanding of the evolution and spread of infections like measles and HIV.
I don’t, however, have any background in engineering, nor in biochemistry. So I have had to get up to speed over the past few years.
At this point let me explain what engineering biology actually is.
Engineering biology involves applying engineering to biological processes in order to bend biology to our will.
In other words, it’s the practice of using ideas and tools taken from engineering to design and modify living organisms or biological systems.
Using tools and ideas developed over recent decades, the goal is to develop new materials and energy sources; to improve animal, plant and human health; to address environmental issues in new and sustainable ways.
What we’re talking about is the ability to harness and control biology predictably, repeatably and – I’ve said this already – usefully. Sometimes that will mean working with what’s already available in nature; at other times, it will involve genetic modification techniques.
Let me unpack some of this a bit further.
Firstly, on the engineering side. Here, I want to start with the design-build-test-learn cycle – DBTL for short.
This approach has been central to product development in engineering disciplines for some time. It drives continuous refinement and innovation, making research and development faster and more efficient.
In engineering biology, design-build-test-learn is brought to bear on biological processes – by which I mean the activities occurring within living organisms.
Image of the design-build-test-learn cycle. Each element is located in a different quarter and all 4 quarters make up a circle.
Essentially, I’m talking about designing something biological – like a version of a cell, or it could be a biological process (such as cell division) or a genetically-engineered system…
Then building it, maybe in the lab…
Then testing it to see how well it works…
Before finally, and perhaps most importantly, learning from what did and didn’t work and then feeding the lessons into another round of design, making improvements again and again around this cycle, towards an end goal.
This looks like being a more efficient way of recycling metals, to use the case study I gave at the start.
And why is this approach necessary? Well, because living organisms are highly complex, with many different parts and networks of interactions between those parts.
One could argue that physical or chemical systems are a bit more straightforward, more predictable, more easily quantifiable. We’ve been using this design-build-test-learn process to bend chemistry and physics to our will for more than a century – very successfully.
The complex and often unpredictable nature of biological systems means we need to work through multiple permutations to get to a desired outcome – and that’s where the engineering in engineering biology comes in.
If we can get this approach right – and I’m going to offer some further examples later showing where we already are – then we have the power to systematically develop biological systems to meet some of the biggest challenges we face.
Let me be more definitive. If the nineteenth century was chemistry’s golden age, and the twentieth century was the same thing for physics, I believe the twenty-first century should be the golden age for biology.
Why am I so optimistic?
This century can belong to biology because of a series of extraordinary advances in scientific understanding.
Where to begin? Of course, we have spent thousands of years modifying the living world.
But I’m not going to go all the way back to the domestication of wild crops. I’m not even going back to Darwin and Mendel.
Instead I’ll start with Watson, Crick and Wilkins – as well as the often overlooked Rosalind Franklin; 3 of the 4 received a Nobel Prize in 1962. By determining the structure of DNA, they discovered what we can call the language of biology.
Understanding the structure of DNA opened the door to reading this complex language, then editing it, then actually writing it ourselves.
Our ability to read DNA took a big step forward thanks to Walter Gilbert and Fred Sanger, who shared half of the 1980 Nobel Prize in Chemistry. Gilbert and Sanger did lots of work to understand the building blocks of DNA – the nucleotide alphabet of biology, if you like.
The next game-changer was in 1983 when an American biochemist, Kary Mullis, developed something called the Polymerase Chain Reaction. Better known as PCR, it is a laboratory technique that’s used to make copies of particular pieces of DNA. Think of it as a photocopier for DNA.
The technique lets scientists easily – and cheaply – create many millions of copies of DNA segments from very small original amounts – and that makes reading the DNA in a sample possible even if it is only there in tiny amounts.
You will all have become familiar with PCR during the Covid pandemic, when it was used to make many copies of the viral genetic material to allow reliable diagnosis of a Covid infection. That was the test where you did a swab, popped it in a test tube and then sent it away in the post. It was particularly important early on, before we had home testing kits.
The invention of PCR also earned a share of the 1993 Nobel Prize in Chemistry – that’s DNA Nobel number 3.
Fast forward 10 years to 2003 and the completion of the Human Genome Project. Researchers across the world spent some 13 years cataloguing the precise sequence of all the DNA in the cells of a human being. It was a huge effort and that first whole genome sequence of a human cost an estimated £2.5 billion.
Thankfully – but also remarkably – sequencing technology has come on leaps and bounds over the past 20 years. Now, it is possible to sequence the same amount of DNA analysed by the Human Genome Project in a single day – and for just a few hundred pounds! We’ve even developed pocket-sized machines which are capable of reading DNA in real-time.
In fact, I have 1 here: a portable sequencing device made by Oxford Nanopore. You simply add your sample into the middle here – this contains the sensor that will help to read the DNA sequence of your sample. Then simply close the lid and press go. And the results are delivered straight to your laptop via a USB-C cable which plugs into the end here.
This is useful for situations where we can’t send off a sample for analysis and wait days for the results – if, say, we’re urgently trying to identify the cause of an infection in some far-flung corner of the world.
So… we’ve learned to amplify DNA using PCR and we’ve learned to read DNA – fast – using rapid sequencing technologies.
We’ve also started learning – and do emphasise “started” – to accurately and precisely “edit” DNA.
Previously, when we wanted to do this, the methods were somewhat cruder – such as gene guns, which were used to literally fire DNA into cells.
We now have tools like CRISPR-Cas9 (another Nobel prize-winning technology developed by Emmanuelle Charpentier and Jennifer Doudna), and we can now take a targeted portion of DNA and change it very accurately in specific places. Some people have compared CRISPR to using a pair of genetic scissors.
Some of you might be wondering whether engineering biology is any different from another common term: synthetic biology. They are often applied interchangeably, although different countries interpret them in different ways.
The way I see it, synthetic biology refers to tools like CRISPR, used to design and build new biological components. Engineering biology is taking these tools – with or without genetic modification – and using the DBTL cycle to apply these tools at scale to find solutions to problems in the world around us.
There are still challenges with the accuracy of such tools, but the possibilities are vast.
We know that certain diseases are caused by mutations in a single gene. Sickle cell disease, for example, is caused by mutations in the beta-globin gene, resulting in red blood cells which are misshapen. As a result, these red cells don’t flow around the body as well as they should. This can cause those affected – roughly 17,500 people in the UK – to suffer from anaemia as well as complications like terrible pain and organ damage.
In the past, the only treatment was to rely on regular blood transfusions or a bone marrow transplant, neither of which comes without risks or complications. However, researchers have been using CRISPR to precisely edit the gene responsible for sickle cell with great success – so much so that, in January this year, the treatment was approved for use in the NHS as the world’s first gene-editing treatment for blood disorders.
And this is just 1 of many gene-editing clinical trials going on right now, including treatments for liver disease, heart disease and some cancers.
The possibilities are not confined to human diseases. We can use these genetic scissors to develop crops that are better at withstanding drought and more resistant to insects, so we don’t have to rely so much on pesticides.
And it’s these tools that are being used to modify the bacteria designed for metal recycling that I spoke about at the start.
Now, it would be remiss of me to talk about the tools of the future without mentioning AI and the transformative impacts it could have.
A prime example is the challenge of understanding and predicting how proteins fold up intricately and precisely in all of our cells. Decoding this process is something scientists have been trying to achieve for decades.
And in 2018, DeepMind came along with its AI model AlphaFold. AlphaFold has since been used to calculate the structure of hundreds of millions of proteins. And, yes, it earned the UK’s Demis Hassabis a share of last year’s Nobel prize in chemistry.
Timeline starting with images of James Watson, Francis Crick, Maurice Wilkins and Rosalind Franklin above the year 1962. Images of Walter Gilbert and Frederick Sanger are next to the year 1980. Image of Kary Mullis is next to the year 1993. Images of Emmanuelle Charpentier and Jennifer Doudna are below the year 2020 and an image of Demis Hassabis is below the year 2024.
All that’s missing on my timeline now is the capacity to design a new protein from scratch de novo. That will bring us into the realm of being able to write the language of biology – designing and printing a sequence of synthetic DNA to produce a protein with the properties that we want, from scratch.
I’ve just been talking about how technologies such as AI, and tools such as CRISPR, are helping to broaden the range of biological powers at our disposal and increase our ability to design and optimise biological systems.
And all this comes with valid concerns about risks. An example which springs to my mind was when scientists in Australia created a version of a mouse virus back in 2001 that instead of causing the normal mild symptoms, killed all of the mice within nine days. They were conducting some innocent genetic engineering research to try and make a mouse contraceptive vaccine for pest control and inadvertently found a way of creating a much more deadly version of the mousepox virus. Unsurprisingly, this made quite a splash in the media – although I think it was good that such a story was not buried.
The point I want to make is that we must develop the right practices and regulation so that we ensure that research is carried out safely and responsibly but we do not stifle innovation.
We refer to this as “responsible innovation” and it is 1 of the pillars of our government vision for engineering biology. That has given rise to new guidance on which genetic sequences people should be allowed to order for their research – welcome progress.
Having the UK take a lead in this kind of responsible innovation – where we are thinking carefully about the desired benefits of our research as well as about how to avoid negative impacts – lets us manage the risks and harness the wealth of opportunities that engineering biology can offer.
There are also other challenges to overcome. What’s standing in the way of us exploiting engineering biology for good? I won’t dwell for long on this, because you’re here to hear about science, not policy – but it is important to talk about the barriers.
We’ve already spoken about proper regulation for engineering biology. We also need to have proper ways of funding the basic research that drives this wonderful new technology and also the application of that research that lets us solve real-world problems. Then there’s also the task of making more people aware of the potential for progress here.
But a key area for me – and also a common issue across all areas of science and technology – is making sure we have the right skills in our future workforce to perform the future jobs that come with new technologies.
The skill set for engineering biology is particularly broad: the field is a combination many different skill-sets and mindsets. Mostly we train people either to become biologists or to become engineers, and for this technology we need people who can think with both those mindsets. So we need to think about a pipeline which starts in schools, with children getting the right grounding in key subjects – and children also hearing about the exciting careers they can pursue through developing and using the technologies I’ve talked about.
I think it’s vital that we don’t think exclusively about technical skills: communication skills are extremely important too. It’s a wonderful thing to do pioneering, cutting-edge research but we also need to be able to explain what that’s about and why people should want it.
So far, I’ve told you a bit about what engineering biology is and how we’ve got to this point, poised for biological century. I’ve also talked a bit about risks and challenges, but I think it’s now time to delve further into the applications that I think are so inspiring.
Today, I launched a report called “Engineering Biology Aspirations”. It’s our attempt to share our excitement about the possibilities that this technology opens up – and we want to share it with everyone, my colleagues inside government and also much more widely.
It contains case studies, written by UK-based experts, that illustrate some of the diverse problems we can address using engineering biology. Microbial metal extraction is 1 of them. I want to highlight some others during the rest of this talk – and to recognise some of the amazing research taking place in the UK.
One of the reasons that I commissioned the report is that all too often, when someone mentions engineering biology or synthetic biology, the examples will involve vaccines or medicines.
Of course those are fantastic, important applications: with the Covid pandemic such a fresh memory, we are all acutely aware of the life-saving importance of rapid and effective vaccine production. And I’m in awe of those researchers who can edit the gene that causes sickle cell disease.
But I want to make sure that we also shine a light on the true breadth of opportunities that engineering biology presents, not only in health, but across agriculture, materials, chemicals, energy, defence.
So, let’s shift gear and think about the fashion industry. Unlike metal recycling, it’s a sector familiar to all of us. We all buy and wear clothes, but we don’t often stop to think about where they’ve come from, how they’ve been made, and at what cost to the environment.
Putting aside issues around workforce conditions and waste, the fashion industry is 1 of the world’s largest polluters, responsible for up to 8 per cent of carbon emissions globally…
Not to mention the pollution generated in the form of clothing and textiles dumped in landfills, like this 1 in Bangladesh, never to biodegrade.
At the same time, 1/5 of the pollution of clean water around the world is caused by dyeing and treating textiles.
And there’s also growing awareness of the environmental damage caused by the microfibres shed by polyester clothing.
So it’s no surprise that plenty of researchers and companies here in the UK and beyond are seeking inspiration from biological processes to make new materials that don’t rely on fossil fuels or on animal products such as leather.
You may have been wondering why there are bottled drinks and a handbag beside each other on the Faraday desk. Well, they’re made of essentially the same material.
The process of making both items starts with microbes that naturally produce a material called nanocellulose.
In the case of Mogu Mogu – a coconut water drink you might find in your local supermarket – the nanocellulose is responsible for the lumps of jelly you can see in this bowl.
It is a polymer produced through fermentation – the same process used to make beer.
Now, 1 company I visited last year is called Modern Synthesis, based in South London and founded by Jen Keane and Ben Reeve. They’re aiming to develop scalable solutions to meet the fashion industry’s need for high-performing, versatile materials that don’t pollute the planet.
Modern Synthesis make nanocellulose fibres and then combine them with textiles such as cotton or linen to create new composites. These are then finished with natural coatings like waxes and oils to improve performance and to enhance look and feel, which are of course critical to customers. The result is this handbag!
Image of black, biologically derived material
And on the slide behind me, you can see in more detail the fibres that make up the handbag. These miniscule nanocellulose fibres are actually really, really strong – 8 times stronger than stainless steel relative to weight!
Modern Synthesis is just 1 example of a pioneering UK company making waves in this area. Another example is Solena Materials who are using AI to help design completely new materials from scratch, including fibres that are effective at absorbing energy. This makes them relevant for the military and the police, who need blast-, ballistic- and stab-proof clothing. As the ex-Chief Scientific Adviser for the Ministry of Defence, it’s great to see engineering biology applications offering benefits for defence.
Developing new materials like these can significantly reduce greenhouse gas emissions compared to traditional material production. This includes minimising the environmental impacts of raising livestock for leather or the energy-intensive processes involved in creating synthetic textiles such as polyesters and nylons. Better still, these materials can be designed for biodegradability, getting away from the big problem of plastic pollution.
Allow me to quote from our report for a second: “Imagine a world where every piece of your clothing has minimal cost to the environment, with zero waste going to landfills. Even if a piece of clothing is accidentally discarded into the environment, it safely biodegrades to leave no trace of its existence. This is the future of fashion, and engineering biology is helping to make it happen.”
Let me move now to another pervasive problem: inefficiencies in food production. Most of you will be aware that fertilisers are used by farmers across the world to supply nitrogen to their crops. Without fertilisers, yields suffer.
But there are 2 problems. First, the process for making nitrogen fertilisers is very energy-intensive. It’s responsible for between 1 and 2% of the entire world’s energy use – and generates matching CO2 emissions. Second, using fertilisers has considerable environmental impacts, releasing further greenhouse gas emissions and damaging waterways thanks to fertiliser runoff from fields.
This slide shows excessive algae growth – a common impact of fertiliser runoff – in the River Wantsum in Kent.
Currently, farmers across the world use more than 200 million tonnes of chemical fertilisers every year.
Diagram showing molecules of nitrogen and hydrogen converted into molecules of ammonia, with a chemical equilibrium sign betweem ammonia and molecules of nitrogen that combine with molecules of hydrogen
Now, this ability to produce nitrogen at scale – via the Haber-Bosch process – was without question the most important chemical breakthrough of the 20th century. The reaction that underpins this industrial process is shown behind me – converting nitrogen and hydrogen into ammonia, which is commonly used in fertilisers. It was discovered by Fritz Haber. Over half the global population depends for survival on foods fertilised using industrial production of nitrogen. But for the reasons I’ve outlined, we do need to do better.
So how can engineering biology help?
What if we could engineer cereals crops to absorb their own nitrogen from the environment, without relying on fertilisers? We call that “fixing” nitrogen.
There are actually examples of this happening in nature. There are bacteria in the soil called rhizobia which are particularly good at fixing nitrogen; in fact, they convert nitrogen gas from the atmosphere into ammonia – which is precisely the form of nitrogen that plants need. Legumes such as peas, clover and lupins attract these rhizobia bacteria to live in their roots – in small structures called nodules. In return for a steady supply of ammonia, the plant houses and feeds the bacteria, forming an ideal symbiotic relationship.
Behind me is an illustration of a plant with root nodules… but in classic Blue Peter style, here are a couple I grew earlier!
This clover plant from my lawn has nodules on its roots – but, because they are a bit tiny, I have also brought a photo of the same plant.
For these sort of plants, we can already coat their seeds with rhizobia and achieve increases in yields. And we can even go a step further by adding the bacteria directly to fields in a process called soil inoculation.
But the trouble with cereal crops like wheat, barley and maize is that they don’t have those root nodules and nor do they produce the special signalling chemicals that legumes use to attract bacteria.
Image showing a clover plant with roots that have small circular nodules on them in the bottom left-hand corner and a sweet-corn plant with roots without nodules in the top right-hand corner
Here is another plant that I’ve brought in from my garden. This 1 is sweet-corn, a variety of maize and a major cereal crop worldwide. You can see its roots here on the top part of the slide… no nodules! These kinds of crops do not set up this kind of symbiotic relationship with nitrogen-fixing bacteria.
So what researchers, like Phil Poole at the University of Oxford, are doing is trying to engineer a new generation of fertiliser-free crops, drawing on plant genetics, biochemistry and soil ecology.
One approach, given what I’ve just described, is to engineer cereals to form nodules on their roots that can host nitrogen-fixing bacteria.
The UK is leading the way on this – Oxford and Cambridge universities have major programmes backed by investment from our research councils and from the Gates Foundation. In fact, the teams involved work together as part of a larger collaboration, and have recently made some significant advances, engineering barley to form nodule-like structures and engineering barley roots to release the chemical signal rhizopine that prompts rhizobia to start fixing nitrogen.
The design-build-test-learn cycle I described earlier is a part of this research. All of the progress made so far has built on round after round of modifying, testing and redesigning organisms.
There are still many hurdles to overcome, both from a technical perspective and societally; genetic modification of crops is a very sensitive issue. But the value of the prize here is large, and I think scientists should not be shy about describing it.
Imagine a world where humanity’s main source of carbohydrates – cereal crops like wheat and barley – are able to generate their own nitrogen fertiliser.
We could tackle global food shortages on a much more sustainable basis and at the same solve 1 of the most urgent climate challenges, consigning industrially-produced nitrogen to the past.
Now, let’s just think about crops in a further context, because harvesting doesn’t have to be the end of their engineering biology journey!
At the start of this talk, I name-dropped a couple of bacterial strains in relation to metal recycling. Well the biologist in me can’t help but tell you another 1 – this time being a type of bacteria called Halomonas.
Researchers like Nigel Scrutton up at the University of Manchester, are engineering these bacteria to act as efficient factories for converting food waste into fuel via fermentation. When I say factories, I’m not talking about the massive industrial sites we would normally associate with fuel production.
This photo is of Fawley oil refinery in Hampshire.
Diagram showing drawings representing bacteria, food waste feedstock, a cylinder that produces fuel and container. The diagram shows that the result of feeding bacteria and food waste feedstock is fermentation that then produces fuel, which can be housed in a portable and scalable container
By contrast, these fuel-producing bacteria can be housed in different-sized containers like the ones on this slide – some of them not too dissimilar to shipping containers.
The beauty of this technology, therefore, is that it is inherently portable and scaleable to meet demand – with transformative implications for remote areas of the world where energy infrastructure can be scarce. And crucially, these are cleaner, fossil-free fuels that can be used to power homes, businesses, even aircraft.
Let’s focus on that last application for a second. At the moment, the aviation industry relies almost completely on kerosene-based fuels, which account for a staggering 3% of global CO2 emissions.
Burning fossil fuels is generally accepted as the main cause of global warming, so it is essential that we find ways to transition to sustainable sources of energy.
Engineering biology solutions like Nigel’s can therefore play a significant role in creating a future without fossil fuels. One of the benefits of using bacteria to turn waste into useful fuels is that this can create another circular economy in which we no longer need to extract and burn more and more harmful fossil fuels; instead we recycle the carbon we already have.
Personally, I think the environmental benefits are reason enough to get excited by this technology. But 1 of the great benefits of bacteria-fuel factories is how portable they are! In other words, they remove the need for large-scale bioreactor infrastructure.
Imagine a world where clean fuels could be produced locally and on demand – including in all those remote and sparsely populated regions which currently struggle to access the fuels they require.
Now, I argued just a moment ago that I want to convince people that engineering biology is about so much more than vaccines and medicines – and I hope that I’ve surprised at least some of you with the breadth of the examples I’ve described so far.
But I do have 1 example from medicine that is just too fascinating to leave out, and that’s research into laboratory-grown blood.
Why would we need such a product?
Currently, the world relies almost entirely on human blood donations to treat disease and for emergency medicine. In many countries, including the UK, donation rates fluctuate, and shortages can happen. On top of that, donated blood has a limited shelf life. It is challenging to store and challenging to distribute. When you consider the fact that some countries don’t have the infrastructure to deliver blood products safely, or think about conflict or humanitarian emergencies, the problems associated with donated blood become even clearer.
There are a few more issues too. It can be very difficult to source some rare blood types. And although blood services of course use screening to avoid known pathogens, there is always a risk of new ones arising, and being passed on to patients who receive blood transfusions.
For all these reasons, finding new ways to produce blood would be another game changer, and, once more engineering biology can help us.
Researchers, like Ash Toye at the University of Bristol, are exploring the possibility of banking unlimited supplies of red blood cells, either by transforming stem cells or genetically reprogramming donated precursor blood cells.
What you can see on the screen is a beautiful illustration by artist Claudia Stocker, which provides a visualisation of CRISPR – the “genetic scissors” technology I mentioned earlier – being used here to edit the genetic material of the precursor cells that will go on to become red blood cells.
The part of the image to focus on is the centre of the slide and specifically the spiral spools of DNA emanating from the big blue circle in the middle – the cell that will eventually give rise to the red blood cells around the outside of the slide. The little blue doughnuts represent the CRISPR technology in action, actively and precisely editing the DNA as we have instructed it to do.
This editing can enable us to produce precursor cells that can grow and divide indefinitely in a controlled environment, giving us unlimited blood supplies.
The Bristol team pioneering this research has been working closely with NHS Blood and Transplant and other partners in a ground-breaking clinical trial called RESTORE – RESTORE being the acronym for REcovery and survival of STem cell Originated REd cells.
It’s the first time in the world that red blood cells grown in a laboratory have been given to another person as part of a trial into blood transfusion – you might have seen media coverage of this programme, which has attracted interest from all over the world. The trial should produce further results by the end of this year or early next.
In the future, we could go a step further and use CRISPR to delete the genes responsible for blood groups, and – in doing so – create “universal” blood that would be invaluable in providing blood transfusions for individuals with rarer blood types.
Image of a table containing the combinations of blood types of a donor and a recipient that match each other and ones that do not. The matches are highlighted in purple and the mismatches in red
This slide is a brief reminder of the complexities around ensuring blood compatibility between donors and recipients. Only the combinations in purple are suitable.
The prospects here are again tantalising. Imagine a world where no patient dies due to a lack of compatible blood following an accident or during surgery. Where safe blood is available on demand, can be stored for longer and is free of disease transmission risks.
So there are all these amazing opportunities, which you can tell I love talking about!
We’ve covered a fair bit of ground about engineering biology: not just historically but geographically, in universities and companies, and across a range of applications.
I’m so proud that our country can lay claim to so much ingenuity. Microbial metal recycling from Edinburgh. Biosynthetic fuels from Manchester. Lab-grown blood from Bristol. Nitrogen-fixing cereals from Oxford. And nanocellulose-based materials from right here in London.
I want to end, though on a broader point concerning emerging technologies such as engineering biology and others besides.
Earlier, you heard me talk about risks and challenges, including the need for responsible innovation.
Another challenge – though – is about how we, as a society, talk about science and technology in general.
Clearly, 1 of my aims this evening has been to raise awareness of engineering biology.
But it strikes me that we’re living through a period where public engagement around science is getting harder.
That’s not just because of the unprecedented volumes of misinformation circulating around us.
We now live in a less paternalistic society – which is surely a good thing – it is no longer enough for scientists to tell people what’s good for them and expect them to toe the line. Instead, we know we need to have a proper, well-informed debate about these issues.
Clearly, it would be possible for the promise of engineering biology to be compromised by public opposition. We need to listen to public concerns – really listen! – and understand that if we don’t respond to those concerns people will be perfectly within their rights to not support, or actively block, the engineering biology advances that we’re trying to create.
There is a lot of work to do here. I don’t think we can ever be finished listening to the public.
Essentially, the technologies we’re developing in engineering biology need to offer solutions to problems that people actually care about.
Health, nutrition, climate, the environment, sustainability, global equity. I know that these are problems that billions of people care about.
I hope I’ve persuaded you that when it comes to these problems, engineering biology can provide solutions.
Image of the front cover of the ‘Engineering Biology Aspirations’ report on the left-hand side and a QR code to the webpage with the report on the right-hand side
Thank you for listening – do read our report; here it is – and thank you to the Royal Institution for asking me to speak in this 200th anniversary year for discourses.
Ms. Anuradha Prasad, former Secretary to the Government of India, Inter State Council Secretariat, Ministry of Home Affairs, took the Oath of the Office and Secrecy as Member, Union Public Service Commission today. The Oath was administered by Lt. Gen. Raj Shukla (Retd.), the seniormost Member of the Commission.
Ms. Anuradha Prasad did her graduation from the Lady Sriram College for Women and obtained a Masters in History from the University of Delhi. She also has a Masters Degree in Development Administration from the University of Birmingham, U.K.
Ms. Anuradha Prasad belongs to the 1986 batch of the Indian Defence Accounts Service. She has extensive experience in public policy, public finance, and cooperative federalism. In a career spanning over 37 years, she has worked in Union Ministries of Defence, Finance, Food Processing Industries, Labour & Employment and Home, gaining in-depth experience in policy & programme formulation and implementation.
As Finance Manager in the Acquisitions Wing of the Ministryof Defence, she handled acquisition of large platforms.In the Ministry of Finance, she handled finance and accounting for the Defence Services and the Ordnance Factory Board.During her stint in the Ministry of Food Processing Industries, Ms. Anuradha Prasad was instrumental in the development of the food industry through cold chain infrastructure, food testing laboratories and industry-driven R&D. She also has regulatory experience as Member of the Board of Food Safety and Standards Authority of India (FSSAI) as also the National Council for Vocational Education & Training (NCVET).
As Additional Secretary in the Ministry of Labour & Employment, she contributed to drafting of the Labour Codes and development of e-Shram Portal, a national database of workers in the unorganized sector.As Director General, Employees’ State Insurance Corporation (ESIC), she spearheaded various initiatives for health & welfare of workers during the Covid-19 pandemic.
As Secretary, Inter State Council Secretariat, Ministry of Home Affairs, she handled Centre-State and Inter-State relations and built consensus on many complex and sensitive issues resulting in key policy changes and expediting of infrastructure and other projects.
Post-retirement, Ms. Anuradha Prasad served as Member, Police Complaints Authority, Government of NCT Delhi.
Source: United Kingdom – Executive Government & Departments
News story
Former St Helens pub landlord failed to declare he was bankrupt when applying for Covid loan
Suspended sentence for former St Helens pub owner
Gary Wright was the owner of the Talbot Ale House in St Helens before it ceased trading in 2019, prior to the pandemic
Wright was subsequently declared bankrupt in early 2020
This did not stop him applying for a £25,000 Bounce Back Loan on behalf of the pub, failing to tell the bank he was bankrupt in the process
The loan was repaid in full earlier this year
A former St Helens pub owner who failed to disclose his bankruptcy when he applied for Covid support funds has been handed a suspended sentence.
Gary Wright did not inform the bank that he was bankrupt when he obtained a £25,000 Bounce Back Loan in the summer of 2020.
The 46-year-old made the application on behalf of the Talbot Ale House on Duke Street in St Helens town centre, the pub he ran before his bankruptcy earlier that year.
Wright, of Bleak Hill Road, St Helens, was sentenced to two years in prison, suspended for two years, at Liverpool Crown Court on Thursday 24 April.
He was also ordered to complete 150 hours of unpaid work and pay £1,500 in costs.
The Bounce Back Loan was repaid in full shortly before Wright was sentenced.
David Snasdell, Chief Investigator at the Insolvency Service, said:
Gary Wright incurred significant debts after his business failed and he was ultimately declared bankrupt.
He then attempted to take advantage of a scheme which was backed by taxpayers and designed to support viable small businesses through the pandemic.
Bankrupts are legally required to declare their status when applying for loans or credit. Wright clearly failed to do this which is why he now has a criminal conviction.
Talbot Ale House ceased trading in September 2019 and Wright was declared bankrupt in February 2020 due to debts owed to a major utility company.
Despite this, Wright applied for a £25,000 Bounce Back Loan in June 2020, claiming the turnover of the pub was £400,000.
Wright remains an undischarged bankrupt, meaning he has not been officially released from his bankruptcy.
Individuals subject to a bankruptcy order must disclose their status if they borrow or obtain credit of £500 or more.
A pub continues to run from the same address but under different management.
Further information
Gary Wright is of Bleak Hill Road, St Helens. His date of birth is 15 December 1978
The payments sector has undergone significant changes in recent decades, driven by digitalisation and the rise of new technologies. While the latter provide opportunities, they also bring risks, particularly in terms of financial stability and sovereignty. These risks have been amplified since the inauguration of the new US administration and the upheavals to the international order that its challenges to multilateralism and its deregulatory and protectionist policies could cause.
Against this backdrop of great uncertainty and the major shocks to the financial system since the start of the month, the financial authorities have an important role to play in fostering stability and trust among the players in the French and European economy and financial system. Accordingly, in addition to ensuring price stability, the objective of the Banque de France, in keeping with its monetary and financial stability mandates, is to help maintain stable access to financial services, particularly credit, and to encourage innovation and diversification. It also strives to ensure the smooth functioning of our economy and the infrastructures on which it relies, and especially our payment system.
In my presentation this morning, I would first like to review the main trends and challenges facing the European payments ecosystem, and then present the levers we are using at the Banque de France to ensure its efficient operation and the security of payment systems and payment means, and to help strengthen Europe’s sovereignty over its payment system.
[Slide 2 – I. Trends and challenges for payments in France and Europe]
I. The digitalisation of payments and its implications
A. Progress in technology is leading to the rapid digitalisation of the payments ecosystem
[Slide 3: A rapid payment digitalisation process]
For a little over a decade now, we have been witnessing a strong move towards digitalisation and the increasing use of electronic payment solutions,with an attendant decrease in the use of cash. Payment cards are now the most commonly used means of payment at the points of sale, accounting for more than 48% of transactions in France in 2024. Conversely, cash payments are gradually decreasing, falling to 43% of point-of-sale transactions in France in 2024, whereas they stood at 50% in 2022, and as high as 68% in 2016.
This trend accelerated even further with the rise of online shopping and the Covid pandemic. The share of e-commerce in the number of transactions thus doubled between 2019 and 2024 to reach a quarter of all transactions in France. At the same time, contactless payments and mobile payments have developed rapidly, with the aim of making payments increasingly seamless and almost invisible to consumers. This trend has been facilitated by the development of new technologies that have modernised payments, such as near-field communication (NFC) and QR codes, which have enabled the roll-out of contactless payments.
Against this backdrop,new players in paymentshave emerged, whose value added stems from technological innovation. These new players are now competing with traditional financial institutions such as banks. They include not only FinTechs but also “non-financial” players, namely telecom operators, technical service providers (specialising, for example, in the tokenisation of payment card data), and BigTechs, in particular the American GAFAMs – ApplePay, GooglePay – which dominate the mobile payments market. They also include Chinese and Korean platforms such as AliPay and WeChatPay.
The growth in the tokenisation of financial instruments, driven by the use of distributed ledger technologies (DLT) such as blockchain,represents a significant opportunity for our markets. Significant benefits are expected: faster exchanges, lower operating costs and greater transparency of transactions. However, this trend is now going hand in hand with a plethora of uncoordinated DLT initiatives, giving rise to the emergence of new private settlement assets, most notably stablecoins. These initiatives are largely controlled by non-European players and mechanisms, whose reference currency is the dollar.
B. The challenges raised by changes in the payments landscape
[Slide 4: Issues and challenges posed by the digitalisation of the European payments system]
While the digitalisation of payment means has delivered many benefits, in particular by enabling simpler, faster, more convenient and more secure payments, it also poseschallenges.
The decline in the use of cash raises questions about thesustainability of some of its characteristics, particularly confidentiality, universal acceptance and accessibility, which are not currently available in the digital sphere. Furthermore, the increase in the use of digital payments raises questions about therole of central bank money, as opposed to commercial money used for card payments, even though central bank money plays a key role in anchoring confidence in our monetary system.
Furthermore, expanding the use of digital solutions has steadily upped our reliance on non-European entities (particularly from the United States and China), which already leverage significant network effects, thanks notably to their ability to harness extensive datasets and customer bases. They also control a number of widely used proprietary standards (Visa, Mastercard). Beyond the question of operational resilience, this situation raises concerns over competition, strategic autonomy and data protection. With the emergence of these international players, European payment solutions appearhighly fragmentedand their market share has been eroding.1
The growing digitalisation of payments also represents a challenge to maintain ahigh level of payment security. Fraud schemes are becoming increasingly complex, involving the manipulation of payers and the circumvention of the strong authentication mechanisms put in place to ensure the security of digital payments in Europe. In particular, artificial intelligence (AI) isa double-edged sword.
AI amplifies cyber riskand, in payments, it can considerably facilitate payment scams, for example through deepfakes. But this technology can also become aninvaluable ally in the fight against fraud, by enabling fraud schemes to be more rapidly and effectively identified. Against this backdrop, integrating AI into anti-fraud models could help to improve the security of the digital payment means available to the public.
It should also be noted that digitalisation could extend to financial assets, through tokenisation, although at present there are no suitable and really secure payment solutions available for these financial transactions.Therefore, without a central bank money-based payment solution for these “wholesale” transactions, private non-European solutions could become dominant, in particular stablecoins. However, almost all stablecoins are currently pegged to the dollar, and their issuance in the United States is not currently subject to any protective federal regulatory framework. If the tokenisation of financial assets were to gather pace, the lack of a central bank money payment solution in euro might therefore threaten the role of central bank money as the anchor of the euro area’s monetary architecture, with concrete adverse consequences: an increase in counterparty and liquidity risks, increased fragmentation of settlement, and ultimately a loss of sovereignty and a weakening of financial stability.
In this context, the recent positions adopted by thenew US administration, and in particular the adoption on 23 January of an Executive order, are likely to amplify these risks as this Executive Order (i) prohibits all work related to the development of a new form of central bank money compatible with technological changes, (ii) promotes the development of dollar-backed stablecoins, and (iii) encourages citizens and businesses to use public blockchains. This new political direction reinforces the need for Europe to preserve its monetary sovereignty, which means developing its payment sovereignty.
II. To meet these challenges, the Banque de France is using several additional levers for action
[Slide 5: Transition – Two additional responses: regulation/support and innovation.]
A. Adapting regulatory frameworks and supporting innovation within a framework of trust
[Slide 6: Adapting regulatory frameworks at national and international level]
First and foremost, the Banque de France promotesclear, standardised and balanced regulatory frameworksthat allow innovation to flourish within a framework of trust conducive to their sustainable deployment. It therefore supports and contributes to the development of frameworks that aim to:
Maintain a level playing field between players. For example, this has made it possible for operators other than Apple to have access to NFC antennae on iPhones at the European level to promote better competition.
Adapt to technological progressto support the development of new players, while ensuring they are adequately regulated, based on the principle of “same activity, same risk, same regulation”. This approach has guided the deployment of the Markets in Crypto-Assets (MiCA) regulation, which standardises the rules applicable to crypto-asset service providers, enabling them to develop their business while ensuring that risks to users and the financial system are properly managed.
Protect consumers. This was, for example, the aim of the second European Payment Services Directive (PSD2), which introduced “strong customer authentication” (SCA) for more secure payments. The Instant Payment Regulation (IPR) follows the same logic, requiring payment service providers (PSPs) to deploy fraud protection measures (e.g. checking the name of the beneficiary against the IBAN) to ensure the orderly development of instant payments.
[Slide 7: Strengthening the security of means of payment]
As part of its statutory mission, which includes ensuring the security of means of payment, the Banque de France supports innovation by ensuring that it does not jeopardisethe security of payment methods. The following tasks are performed within the framework of the Observatory for the Security of Payment Means (OSMP).
Communication campaignstargeting the general public, such as “never give out your data”, carried by various audio-visual media and radio, and aiming to raise awareness of the personal nature of passwords in particular,
Initiatives aimed atboosting cooperationwith data protection, cybersecurity and telecommunications authorities to limit fraud as much as possible.
[Slide 8: Promoting innovation by supporting private initiatives]
Support for innovation also seeks to ensure that private initiativeshelp to strengthen European sovereignty over the euro payment system:
At the national level, this support aims to consolidate the position of high-performance French payment solutions, such as theGroupement carte bancaire(CB bank card group), which has been allocated specific support within the framework of the new national retail payments strategy for 2025-30, implemented by the National Payments Committee (CNMP) last October.
At the European level, pan-European solutions, such as the European Payments Initiative (EPI), are strongly supported. EPI launched the ‘Wero’ digital payment wallet for consumers last autumn, providing instant payments across five European countries (Belgium, France, Germany, Luxembourg and the Netherlands). This initiative with pan-European ambition aims to promote competition and strengthen Europe’s strategic autonomy in retail payments.
B. The provision of new central bank money services to preserve the key role of central bank money in a digitalised world
Alongside regulating and supporting private initiatives, the Banque de France is making a strong and decisive contribution to the Eurosystem’s work on developing its services through the creation of a central bank digital currency for both retail and wholesale transactions. This work has become more strategically important in terms of ensuring European sovereignty over its payment system since the policy shift initiated by the new US administration that I referred to a few minutes ago.
[Slide 9: Innovating with the digital euro: a European payment solution]
1. The digital euro
Given the strong dependence on American payment solutions and networks, the Banque de France thus supports and participates fully in the digital euro project spearheaded by the Eurosystem, which will constitute a public alternative, preserving the freedom to choose means of payment, sovereignty and competition in the euro area.
The digital euro aims to provide everyone with the possibility to use a ‘digital banknote’ in the digital payments spherethat incorporates the main features of a ‘physical’ banknote. Itsoff-linemechanism will provide a cash-like level of privacy and will be a guarantee of resilience. It will befree of chargefor individuals. Its characteristics will fosterdigital financial inclusion, including for people without bank accounts or smartphones. It will also be anew form of public money, which will safeguard the anchoring role of central bank money and trust in our single currency.
The digital euro also aims to strengthenEuropeanintegration and strategic autonomy in payments thanks to thelegal tenderstatus it would be given, making it usable anywhere and in any circumstances within the euro area. It will also be based onopen and harmonised standards, which private payment solutions such as Wero will be able to use to expand their reach. In this way, the digital euro aims to foster the development of private solutions under European governance, which can be used across the euro area, whereas most solutions are currently restricted to certain countries or use cases.
The Eurosystem is currently in apreparation phasethat will last until the end of 2025. At the same time, a democratic debate is taking place at the European level to define, by means of legislation, the conditions in which the digital euro may be used. A decision on issuance can be taken once this legislation has been approved by the European Parliament and the Council.
[Slide 10: From Wholesale CBDC to a shared European ledger]
2. Wholesale central bank digital currency
With the development of tokenised assets, the Banque de France is also firmly committed to providing a payment solution in central bank money that includes making it available in tokenised form, in other words, a “wholesale CBDC”.
The Banque de France has been resolutely committed to this solution since 2020, playing a pioneering role at the European level in an experimental programme conducted between 2020 and 2022, in partnership with various private and institutional sector players. This work, which allowed the Banque de France to develop and test its own blockchain (DL3S), was followed by that of the Eurosystem in 2024. This was used to test three solutions for settling tokenised assets in central bank currency through around 40 or so experiments.
Drawing on the lessons learned from these experiments and their confirmation of a demand for adapting central bank money services, in February 2025, the ECB Governing Council decided to quickly make available a settlement service in CB money adapted for tokenised assets, which will include money in token form, i.e. a “wholesale” CB digital currency.
This decision also paves the way for discussions on building a European shared ledger that could be used to adapt European payment infrastructures to the digital era to ensure sovereignty.By providing a credible alternative to non-European solutions, based on a standardised legal and regulatory framework, a European shared ledger could support financial integration within the EU and help strengthen the resilience and attractiveness of our financial market.
Conclusion :As a central bank tasked with safeguarding monetary and financial stability, and notably the security and efficiency of payment systems and means of payment for the euro, the Banque de France is fully committed to monitoring, understanding and supporting the major transformations currently taking place in the payments landscape. These transformations have recently assumed major strategic importance for the monetary sovereignty of euro area countries, necessitating the mobilisation of all the European players concerned to respond in an appropriate and adequate manner. This involves developing secure, efficient public and private pan-European payment solutions that contribute to European sovereignty over its payment system. As both supervisor and provider of central bank money services, we are determined to play our part.
Reports First Quarter 2025 Total Revenues of $34.9 million
Recurring Revenues Grew 10% from Prior Year
AUSTIN, Texas, May 01, 2025 (GLOBE NEWSWIRE) — Asure Software, Inc. (“we”, “us”, “our”, “Asure” or the “Company”) (Nasdaq: ASUR), a leading provider of cloud-based Human Capital Management (“HCM”) software solutions, today reported results for the first quarter ended March 31, 2025.
First Quarter 2025 Financial Highlights
Revenue of $34.9 million, up 10% year over year, excluding ERTC revenue up 13% from the prior year first quarter
Recurring revenue of $33.2 million versus $30.3 million during the prior year first quarter
Net loss of $2.4 million versus a net loss of $0.3 million during the prior year first quarter
EBITDA(1) of $4.1 million versus $4.4 million during the prior year first quarter
Adjusted EBITDA(1) of $7.3 million versus $6.8 million during the prior year first quarter
Gross profit of $24.6 million versus $22.6 million during the prior year first quarter
Non-GAAP gross profit(1) of $26.3 million (Non-GAAP gross margin(1) of 75%) versus $23.8 million (and 75% in prior year first quarter)
Recent Business Highlights
New Payroll Tax Management solution launched which is designed specifically for large Canadian companies and global enterprises with employees in Canada. Our ability to serve enterprise clients with international workforces with this innovative solution creates further opportunities to grow our business and the seamless integration of payroll tax services into major platforms such as Workday, Oracle, and SAP is a key benefit. The Canadian payroll tax solution addresses critical compliance needs for organizations managing cross-border payroll processes, reducing complexity and ensuring accurate, timely filing.
In April 2025 we entered into a credit agreement primarily with MidCap Financial Trust, whereby the Company may borrow up to $60 million. At closing, which occurred on April 10, we received $20 million of gross proceeds.
(1)This financial measure is not calculated in accordance with GAAP and is defined on page 3 of this press release. A reconciliation of this non-GAAP measure to the most applicable GAAP measure begins on page 11 of this release.
Management Commentary
“We are excited to be off to a great start to 2025 with healthy results for our first quarter of 2025 with our revenues increasing 10% from the prior year first quarter. Our results were driven by strong performance coming from our Payroll Tax Management and initial contribution from our recently acquired product offerings,” said Asure Chairman and CEO Pat Goepel.
“Our team is focused on continuing to execute our growth strategy. Our revenues are now more than 95% recurring, our contracted revenue backlog sits at an all-time high, and we believe that the investments we have made in the business will continue to drive greater adoption of our broadened product suite for the remainder of 2025.”
Second Quarter 2025 and Full Year 2025 Revenue Guidance Ranges
The Company is providing the following guidance for the second quarter of 2025 and the full year 2025 based on the Company’s year-to-date results and recent business trends. The guidance for our second quarter of 2025 and the full year 2025 excludes any contribution from future potential acquisitions.
Guidance for 2025
Guidance Range
Q2-2025
FY-2025
Revenue
$
30.0 M – 32.0 M
$
134.0 M -138.0 M
Adjusted EBITDA(1)
$
5.0 M -6.0 M
23% -24%
Management uses GAAP, non-GAAP and adjusted measures when planning, monitoring, and evaluating the Company’s performance. The primary purpose of using non-GAAP and adjusted measures is to provide supplemental information that may prove useful to investors and to enable investors to evaluate the Company’s results in the same way management does.
Management believes that supplementing GAAP disclosures with non-GAAP and adjusted disclosures provides investors with a more complete view of the Company’s operational performance and allows for meaningful period-to-period comparisons and analysis of trends in the Company’s business. Further, to the extent that other companies use similar methods in calculating adjusted financial measures, the provision of supplemental non-GAAP and adjusted information can allow for a comparison of the Company’s relative performance against other companies that also report non-GAAP and adjusted operating results.
Management has not provided a reconciliation of guidance of GAAP to non-GAAP or adjusted disclosures because management is unable to predict the nature and materiality of non-recurring expenses without unreasonable effort.
Management’s projections are based on management’s current beliefs and assumptions about the Company’s business, and the industry and the markets in which it operates; there are known and unknown risks and uncertainties associated with these projections. There can be no assurance that our actual results will not differ from the guidance set forth above. The Company assumes no obligation to update publicly any forward-looking statements, including its 2025 earnings guidance, whether as a result of new information, future events or otherwise. Please refer to the “Use of Forward-Looking Statements” disclosures on page 5 of this press release as well as the risk factors in our quarterly and annual reports on file with the Securities and Exchange Commission for more information about risk that affect our business and industry.
Conference Call Details
Asure management will host a conference call on Thursday, May 1, 2025, at 3:30 pm Central (4:30 pm Eastern). Asure Chairman and CEO Pat Goepel and CFO John Pence will participate in the conference call followed by a question-and-answer session. The conference call will be broadcast live and available for replay via the investor relations section of the Company’s website. Analysts may participate on the conference call by dialing 877-407-9219 or 201-689-8852.
About Asure Software, Inc.
Asure (Nasdaq: ASUR) provides cloud-based Human Capital Management (HCM) software solutions that assist organizations of all sizes in streamlining their HCM processes. Asure’s suite of HCM solutions includes HR, payroll, time and attendance, benefits administration, payroll tax management, and talent management. The company’s approach to HR compliance services incorporates AI technology to enhance scalability and efficiency while prioritizing client interactions. For more information, please visit www.asuresoftware.com.
Non-GAAP and Adjusted Financial Measures
This press release includes information about non-GAAP gross profit, non-GAAP sales and marketing expense, non-GAAP general and administrative expense, non-GAAP research and development expense, EBITDA, EBITDA margin, adjusted EBITDA, and adjusted EBITDA margin. These non-GAAP and adjusted financial measures are measurements of financial performance that are not prepared in accordance with U.S. generally accepted accounting principles and computational methods may differ from those used by other companies. Non-GAAP and adjusted financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with the Company’s Condensed Consolidated Financial Statements prepared in accordance with GAAP. Non-GAAP and adjusted financial measures are reconciled to GAAP in the tables set forth in this release and are subject to reclassifications to conform to current period presentations.
Non-GAAP gross profit differs from gross profit in that it excludes amortization, share-based compensation, and one-time items.
Non-GAAP sales and marketing expense differs from sales and marketing expense in that it excludes share-based compensation and one-time items.
Non-GAAP general and administrative expense differs from general and administrative expense in that it excludes share-based compensation and one-time items.
Non-GAAP research and development expense differs from research and development expense in that it excludes share-based compensation and one-time items.
EBITDA differs from net income (loss) in that it excludes items such as interest, income taxes, depreciation, and amortization. Asure is unable to predict with reasonable certainty the ultimate outcome of these exclusions without unreasonable effort.
Adjusted EBITDA differs from EBITDA in that it excludes share-based compensation, other income (expense), net and one-time expenses. Asure is unable to predict with reasonable certainty the ultimate outcome of these exclusions without unreasonable effort.
All adjusted and non-GAAP measures presented as “margin” are computed by dividing the applicable adjusted financial measure by total revenue.
Specifically, as applicable to the respective financial measure, management is adjusting for the following items when calculating non-GAAP and adjusted financial measures as applicable for the periods presented. No additional adjustments have been made for potential income tax effects of the adjustments based on the Company’s current and anticipated de minimis effective federal tax rate, resulting from the Company’s continued losses for federal tax purposes and its tax net operating loss balances.
Share-Based Compensation Expenses. The Company’s compensation strategy includes the use of share-based compensation to attract and retain employees and executives. It is principally aimed at aligning their interests with those of our stockholders and at long-term employee retention, rather than to motivate or reward operational performance for any particular period. Thus, share-based compensation expense varies for reasons that are generally unrelated to operational decisions and performance in any particular period.
Depreciation. The Company excludes depreciation of fixed assets. Also included in the expense is the depreciation of capitalized software costs.
Amortization of Purchased Intangibles. The Company views amortization of acquisition-related intangible assets, such as the amortization of the cost associated with an acquired company’s research and development efforts, trade names, customer lists and customer relationships, and acquired lease intangibles, as items arising from pre-acquisition activities determined at the time of an acquisition. While these intangible assets are continually evaluated for impairment, amortization of the cost of purchased intangibles is a static expense, one that is not typically affected by operations during any particular period.
Interest Expense, Net. The Company excludes accrued interest expense, the amortization of debt discounts and deferred financing costs.
Income Taxes. The Company excludes income taxes, both at the federal and state levels.
One-Time Expenses. The Company’s adjusted financial measures exclude the following costs to normalize comparable reporting periods, as these are generally non-recurring expenses that do not reflect the ongoing operational results. These items are typically not budgeted and are infrequent and unusual in nature.
Settlements, Penalties and Interest. The Company excludes legal settlements, including separation agreements, penalties and interest that are generally one-time in nature and not reflective of the operational results of the business.
Acquisition and Transaction Related Costs. The Company excludes these expenses as they are transaction costs and expenses that are generally one-time in nature and not reflective of the underlying operational results of our business. Examples of these types of expenses include legal, accounting, regulatory, other consulting services, severance and other employee costs.
Other non-recurring Expenses. The Company excludes these as they are generally non-recurring items that are not reflective of the underlying operational results of the business and are generally not anticipated to recur. Some examples of these types of expenses, historically, have included write-offs or impairments of assets, demolition of office space and cybersecurity consultants.
Other (Expense) Income, Net. The Company’s adjusted financial measures exclude Other (Expense) Income, Net because it includes items that are not reflective of the underlying operational results of the business, such as loan forgiveness, adjustments to contingent liabilities and credits earned as part of the CARES Act, passed by Congress in the wake of the coronavirus pandemic.
Use of Forward-Looking Statements
This press release contains certain statements made by management that may constitute “forward- looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements about our financial results may include expected or projected U.S GAAP and other operating and non-operating results. The words “believe,” “may,” “will,” “estimate,” “projects,” “anticipate,” “intend,” “expect,” “should,” “plan,” and similar expressions are intended to identify forward-looking statements. Examples of “forward-looking statements” include statements we make regarding our operating performance, future results of operations and financial position, revenue growth, earnings or other projections. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. The achievement or success of the matters covered by such forward-looking statements involves risks, uncertainties and assumptions, over many of which we have no control. If any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our results could differ materially from the results expressed or implied by the forward-looking statements we make.
The risks and uncertainties referred to above include—but are not limited to—risks associated with breaches of the Company’s security measures; risks related to material weaknesses; possible fluctuations in the Company’s financial and operating results; privacy concerns and laws and other regulations may limit the effectiveness of our applications; the financial and other impact of any previous and future acquisitions; domestic and international regulatory developments, including changes to or applicability to our business of privacy and data securities laws, money transmitter laws and anti-money laundering laws; regulatory pressures on economic relief enacted as a result of the COVID-19 pandemic that change or cause different interpretations with respect to eligibility for such programs; risk of our software and solutions not functioning adequately; interruptions, delays or changes in the Company’s services or the Company’s Web hosting; may incur debt to meet future capital requirements; volatility and weakness in bank and capital markets; access to additional capital; significant costs as a result of operating as a public company; the expiration of Employee Retention Tax Credits (“ERTC”) and the impact of the Internal Revenue Service recent measures regarding ERTC claims and the corresponding cash collections of existing receivables; the inability to continue to release timely updates for changes in laws; the inability to develop new and improved versions of the Company’s services and technological developments; customer’s nonrenewal of their agreements and other similar changes could negatively impact revenue, operating results and financial conditions; the exposure of market, interest, credit and liquidity risk on client funds held int rust; the Company’s operation in highlight competitive markets; risk that our clients could have insufficient funds that could result in limitations in the ability to transmit ACH transactions; impairment of intangible assets; litigation and any related claims, negotiations and settlements, including with respect to intellectual property matters or industry-specific regulations; various financial aspects of the Company’s Software-as-a-Service model; adverse effects to our business a result of claims, lawsuits, and other proceedings; issues in the use of artificial intelligence in our HCM products and services; adverse changes to financial accounting standards to the Company; inability to maintain third-party licensed software; evolving regulation of the Internet, changes in the infrastructure underlying the Internet or interruptions in Internet; factors affecting the Company’s deferred tax assets and ability to value and utilize them; the nature of the Company’s business model; inability to adopt new or correctly interpret existing money service and money transmitter business status; the Company’s ability to hire, retain and motivate employees and manage the Company’s growth; interruptions to supply chains and extended shut down of businesses; potential enactment of adverse tax laws, regulation, political, economic and social factors; potential sales of a substantial number of shares of our common stock along with its volatility; risks associate with potential equity-related transactions including dividends, rights under the stockholder plan to discourage certain actions and other impacts as a result of actions of our stockholders.
Please review the Company’s risk factors in its annual report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 6, 2025.
ASURE SOFTWARE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except per share amounts)
March 31, 2025
December 31, 2024
ASSETS
Current assets:
Cash and cash equivalents
$
14,076
$
21,425
Accounts receivable, net of allowance for credit losses of $6,545 and $6,328 at March 31, 2025 and December 31, 2024, respectively
15,800
18,154
Inventory
220
195
Prepaid expenses and other current assets
5,970
4,888
Total current assets before funds held for clients
36,066
44,662
Funds held for clients
257,019
192,615
Total current assets
293,085
237,277
Property and equipment, net
20,999
19,669
Goodwill
94,724
94,724
Intangible assets, net
73,003
69,114
Operating lease assets, net
4,403
4,041
Other assets, net
12,727
11,813
Total assets
$
498,941
$
436,638
LIABILITIES AND STOCKHOLDERS’EQUITY
Current liabilities:
Current portion of notes payable
$
7,948
$
7,008
Accounts payable
2,475
1,364
Accrued compensation and benefits
2,911
4,485
Operating lease liabilities, current
1,432
1,438
Other accrued liabilities
6,071
6,600
Deferred revenue
4,662
8,363
Total current liabilities before client fund obligations
25,499
29,258
Client fund obligations
258,586
194,378
Total current liabilities
284,085
223,636
Long-term liabilities:
Deferred revenue
3,321
3,430
Deferred tax liability
2,903
2,612
Notes payable, net of current portion
6,172
5,709
Operating lease liabilities, noncurrent
3,892
3,578
Other liabilities
905
358
Total long-term liabilities
17,193
15,687
Total liabilities
301,278
239,323
Stockholders’ equity:
Preferred stock, $0.01 par value; 1,500 shares authorized; none issued or outstanding
—
—
Common stock, $0.01 par value; 44,000 shares authorized; 27,122 and 26,671 shares issued, 27,122 and 26,671 shares outstanding at December 31, 2024 and December 31, 2023, respectively
271
267
Treasury stock at cost, zero(1)at March 31, 2025 and December 31, 2024
—
—
Additional paid-in capital
507,149
504,849
Accumulated deficit
(309,624
)
(307,226
)
Accumulated other comprehensive loss
(133
)
(575
)
Total stockholders’ equity
197,663
197,315
Total liabilities and stockholders’ equity
$
498,941
$
436,638
(1) The aggregate Treasury stock of prior repurchases of the Company’s own common stock was retired and subsequently issued effective January 1, 2024. See the Consolidated Statement of Changes in Stockholders’ Equity for the impact of this transaction.
ASURE SOFTWARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (in thousands, except per share amounts)
Three Months Ended March 31,
2025
2024
Revenue:
Recurring
$
33,187
$
30,273
Professional services, hardware and other
1,667
1,379
Total revenue
34,854
31,652
Cost of sales
10,246
9,045
Gross profit
24,608
22,607
Operating expenses:
Sales and marketing
8,386
7,767
General and administrative
11,900
10,063
Research and development
2,029
1,769
Amortization of intangible assets
4,308
3,449
Total operating expenses
26,623
23,048
Loss from operations
(2,015
)
(441
)
Interest income
171
336
Interest expense
(451
)
(180
)
Other income, net
188
10
Loss from operations before income taxes
(2,107
)
(275
)
Income tax expense
291
33
Net loss
(2,398
)
(308
)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities
442
(244
)
Comprehensive loss
$
(1,956
)
$
(552
)
Basic and diluted loss per share
Basic
$
(0.09
)
$
(0.01
)
Diluted
$
(0.09
)
$
(0.01
)
Weighted average basic and diluted shares
Basic
26,961
25,334
Diluted
26,961
25,334
ASURE SOFTWARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands)
Three Months Ended March 31,
2025
2024
Cash flows from operating activities:
Net loss
$
(2,398
)
$
(308
)
Adjustments to reconcile loss to net cash provided by (used in) operations:
Depreciation and amortization
5,972
4,860
Amortization of operating lease assets
374
335
Amortization of debt financing costs and discount
253
142
Non-cash interest expense
197
—
Net accretion of discounts and amortization of premiums on available-for-sale securities
(110
)
(78
)
Provision for expected losses
93
46
Provision for deferred income taxes
291
24
Net realized gains on sales of available-for-sale securities
(656
)
(652
)
Share-based compensation
1,863
1,902
Changes in operating assets and liabilities:
Accounts receivable
2,261
(919
)
Inventory
(24
)
(50
)
Prepaid expenses and other assets
(1,049
)
(473
)
Operating lease right-of-use assets
—
30
Accounts payable
903
(960
)
Accrued expenses and other long-term obligations
(1,737
)
(2,665
)
Operating lease liabilities
(427
)
(141
)
Deferred revenue
(3,810
)
(5,040
)
Net cash provided by (used in) operating activities
1,996
(3,947
)
Cash flows from investing activities:
Acquisition of intangible assets
(6,346
)
(710
)
Purchases of property and equipment
(192
)
(240
)
Software capitalization costs
(2,769
)
(2,435
)
Purchases of available-for-sale securities
(6,589
)
(3,516
)
Proceeds from sales and maturities of available-for-sale securities
3,266
2,406
Net cash used in investing activities
(12,630
)
(4,495
)
Cash flows from financing activities:
Payments made on amounts due for the acquisition of intangibles
(723
)
(236
)
Net proceeds from issuance of common stock
441
176
Net change in client fund obligations
64,207
21,122
Net cash provided by financing activities
63,925
21,062
Net increase in cash, cash equivalents, restricted cash, and restricted cash equivalents
53,291
12,620
Cash, cash equivalents, restricted cash and restricted cash equivalents, beginning of period
145,712
177,622
Cash, cash equivalents, restricted cash and restricted cash equivalents, end of period
$
199,003
$
190,242
ASURE SOFTWARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (continued) (in thousands)
Three Months Ended March 31,
2025
2024
Reconciliation of cash, cash equivalents, restricted cash, and restricted cash equivalents to the Condensed Consolidated Balance Sheets
Cash and cash equivalents
$
14,076
$
23,166
Restricted cash and restricted cash equivalents included in funds held for clients
184,927
167,076
Total cash, cash equivalents, restricted cash, and restricted cash equivalents
$
199,003
$
190,242
Supplemental information:
Cash paid for interest
$
125
$
—
Non-cash investing and financing activities:
Acquisition of intangible assets
$
750
$
6,345
Notes payable issued for acquisitions
$
1,150
$
827
Shares issued for acquisitions
$
—
$
4,494
ASURE SOFTWARE, INC. RECONCILIATION OF NON-GAAP AND ADJUSTED FINANCIAL MEASURES (unaudited)
(in thousands)
Q1-25
Q4-24
Q3-24
Q2-24
Q1-24
Q4-23
Q3-23
Q2-23
Revenue(1)
$
34,854
$
30,792
$
29,304
$
28,044
$
31,652
$
26,264
$
29,334
$
30,420
Gross Profit to non-GAAP Gross Profit
Gross Profit
$
24,608
$
20,928
$
19,704
$
18,868
$
22,607
$
17,839
$
21,280
$
22,018
Gross Margin
70.6
%
68.0
%
67.2
%
67.3
%
71.4
%
67.9
%
72.5
%
72.4
%
Share-based Compensation
44
44
44
43
40
32
28
46
Depreciation
1,369
1,190
1,232
1,145
1,110
921
984
1,309
Amortization – intangibles
50
50
50
50
50
50
50
50
One-time expenses
Settlements, penalties & interest
29
25
2
3
—
(6
)
8
—
Acquisition and transaction costs
167
221
367
264
39
—
—
—
Other non-recurring expenses
—
84
—
—
—
—
—
—
Non-GAAP Gross Profit
$
26,267
$
22,542
$
21,399
$
20,373
$
23,846
$
18,836
$
22,350
$
23,423
Non-GAAP Gross Margin
75.4
%
73.2
%
73.0
%
72.6
%
75.3
%
71.7
%
76.2
%
77.0
%
Sales and Marketing Expense to non-GAAP Sales and Marketing Expense
Sales and Marketing Expense
$
8,386
$
6,945
$
6,680
$
6,924
$
7,767
$
6,422
$
6,597
$
8,515
Share-based Compensation
322
251
269
237
243
180
210
149
Depreciation
1
—
1
—
1
1
—
—
One-time expenses
Settlements, penalties & interest
51
78
(5
)
5
18
6
30
4
Acquisition and transaction costs
30
9
68
37
11
—
—
—
Other non-recurring expenses
—
52
—
—
—
—
—
180
Non-GAAP Sales and Marketing Expense
$
7,982
$
6,555
$
6,347
$
6,645
$
7,494
$
6,235
$
6,357
$
8,182
General and Administrative Expense to non-GAAP General and Administrative Expense
General and Administrative Expense
$
11,900
$
9,940
$
10,378
$
10,118
$
10,063
$
9,747
$
9,294
$
10,336
Share-based Compensation
1,407
1,081
1,187
1,122
1,535
980
936
1,298
Depreciation
244
269
264
256
251
225
200
234
One-time expenses
Settlements, penalties & interest
492
142
377
304
98
284
101
432
Acquisition and transaction costs
491
282
371
245
57
51
—
—
Other non-recurring expenses
136
220
253
—
86
53
—
453
Non-GAAP General and Administrative Expense
$
9,130
$
7,946
$
7,926
$
8,191
$
8,036
$
8,154
$
8,057
$
7,919
Research and Development Expense to non-GAAP Research and Development Expense
Research and Development Expense
$
2,029
$
2,103
$
1,973
$
1,962
$
1,769
$
1,739
$
1,803
$
1,325
Share-based Compensation
90
87
90
86
85
69
76
89
Depreciation
1
—
$
—
$
—
$
—
$
—
$
—
$
—
One-time expenses
Settlements, penalties & interest
9
21
—
27
31
—
—
—
Acquisition and transaction costs
91
153
195
369
147
—
—
—
Other non-recurring expenses
—
29
—
—
—
—
—
—
Non-GAAP Research and Development Expense
$
1,838
$
1,813
$
1,688
$
1,480
$
1,506
$
1,670
$
1,727
$
1,236
(1)Note that first quarters are seasonally strong as recurring year-end W2/ACA revenue is recognized in this period.
ASURE SOFTWARE, INC. RECONCILIATION OF NON-GAAP AND ADJUSTED FINANCIAL MEASURES (cont.) (unaudited)
(in thousands)
Q1-25
Q4-24
Q3-24
Q2-24
Q1-24
Q4-23
Q3-23
Q2-23
Revenue(1)
$
34,854
$
30,792
$
29,304
$
28,044
$
31,652
$
26,264
$
29,334
$
30,420
GAAP Net Loss to Adjusted EBITDA
GAAP Net Loss
$
(2,398
)
$
(3,204
)
$
(3,901
)
$
(4,360
)
$
(308
)
$
(3,582
)
$
(2,206
)
$
(3,765
)
Interest expense, net
280
211
109
(53
)
(156
)
(24
)
782
1,593
Income taxes
291
499
170
231
33
(158
)
(123
)
627
Depreciation
1,614
1,460
1,497
1,402
1,361
1,148
1,185
1,542
Amortization – intangibles
4,358
4,482
4,345
4,096
3,499
3,743
3,384
3,343
EBITDA
$
4,145
$
3,448
$
2,220
$
1,316
$
4,429
$
1,127
$
3,022
$
3,340
EBITDA Margin
11.9
%
11.2
%
7.6
%
4.7
%
14.0
%
4.3
%
10.3
%
11.0
%
Share-based Compensation
1,863
1,463
1,591
1,488
1,902
1,260
1,251
1,582
One Time Expenses
Settlements, penalties & interest
581
266
375
339
147
283
140
436
Acquisition and transaction costs
779
665
1,001
914
254
51
—
—
Other non-recurring expenses
136
385
253
—
86
53
—
633
Other expense (income), net
(188
)
2
—
—
(10
)
1
1,800
93
Adjusted EBITDA
$
7,316
$
6,229
$
5,440
$
4,057
$
6,808
$
2,775
$
6,213
$
6,084
Adjusted EBITDA Margin
21.0
%
20.2
%
18.6
%
14.5
%
21.5
%
10.6
%
21.2
%
20.0
%
(1)Note that first quarters are seasonally strong as recurring year-end W2/ACA revenue is recognized in this period.
Source: US Department of Health and Human Services – 2
News Release Thursday, May 1, 2025
The U.S. Department of Health and Human Services (HHS) and the National Institutes for Health (NIH) today announced the development of the next-generation, universal vaccine platform, Generation Gold Standard, using a beta-propiolactone (BPL)-inactivated, whole-virus platform. This initiative represents a decisive shift toward transparency, effectiveness, and comprehensive preparedness, funding the NIH’s in-house development of universal influenza and coronavirus vaccines, including candidates BPL-1357 and BPL-24910. These vaccines aim to provide broad-spectrum protection against multiple strains of pandemic-prone viruses such as H5N1 avian influenza and coronaviruses including SARS-CoV-2, SARS-CoV-1, and MERS-CoV. “Our commitment is clear: every innovation in vaccine development must be grounded in gold standard science and transparency, and subjected to the highest standards of safety and efficacy testing,” said HHS Secretary Robert F. Kennedy, Jr. The program realigns BARDA’s operations with its statutory mission under the Public Health Service Act—to prepare for all influenza viral threats, not just those currently circulating. “Generation Gold Standard is a paradigm shift,” said NIH Director Dr. Jay Bhattacharya. “It extends vaccine protection beyond strain-specific limits and prepares for flu viral threats – not just today’s, but tomorrow’s as well – using traditional vaccine technology brought into the 21st century.” Generation Gold Standard, developed exclusively by NIH’s National Institute of Allergy and Infectious Diseases (NIAID):
Recalibrates America’s pandemic preparedness. Unlike traditional vaccines that target specific strains, BPL-inactivated whole-virus vaccines preserve the virus’s structural integrity while eliminating infectivity. This approach induces robust B and T cell immune responses and offers long-lasting protection across diverse viral families. Moreover, the intranasal formulation of BPL-1357 is currently in Phase Ib and II/III trials and is designed to block virus transmission—an innovation absent from current flu and COVID-19 vaccines. Embodies efficient, transparent, and government-led research. The BPL platform is fully government-owned and NIH-developed. This approach ensures radical transparency, public accountability, and freedom from commercial conflicts of interest. Marks the future of vaccine development. In addition to influenza and coronavirus, the BPL platform is adaptable for future use against respiratory syncytial virus (RSV), metapneumovirus, and parainfluenza. It also offers the unprecedented capability to protect against avian influenza without inducing antigenic drift—a major step forward in proactive pandemic prevention.
Clinical trials for universal influenza vaccines are scheduled to begin in 2026, with Food and Drug Administration (FDA) approval targeted for 2029. The intranasal BPL-1357 flu vaccine, currently in advanced trials, is also on track for FDA review by 2029. About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov. NIH…Turning Discovery Into Health® ###
LITTLE ROCK, Ark., May 01, 2025 (GLOBE NEWSWIRE) — Inuvo, Inc. (NYSE American: INUV), a leading provider of artificial intelligence AdTech solutions, will host a conference call on Friday, May 9, 2025, at 8:30 AM Eastern Time to discuss its financial results and provide a business update for the first quarter ended March 31, 2025.
Conference Call Details: Date: Friday, May 9, 2025 Time: 8:30 a.m. Eastern Time Toll-free Dial-in Number: 1-800-717-1738 International Dial-in Number: 1- 646-307-1865 Conference ID: 11109974 Webcast Link: HERE
A telephone replay will be available through Friday, May 23, 2025. To access the replay, please dial 1- 844-512-2921 (domestic) or 1- 412-317-6671 (international). At the system prompt, please enter the code 11109974 followed by the # sign. You will then be prompted for your name, company, and phone number. Playback will then automatically begin.
About Inuvo
Inuvo®, Inc. (NYSE American: INUV) is a market leader in Artificial Intelligence built for advertising. Its IntentKey AI solution is a first-of-its-kind proprietary and patented technology capable of identifying and actioning to the reasons why consumers are interested in products, services, or brands, not who those consumers are. To learn more, visit www.inuvo.com.
Safe Harbor / Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Inuvo’s quarter-end financial close process and preparation of financial statements for the quarter that are subject to risks and uncertainties that could cause results to be materially different than expectations. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including, without limitation risks detailed from time to time in our filings with the Securities and Exchange Commission (the “SEC”), and represent our views only as of the date they are made and should not be relied upon as representing our views as of any subsequent date. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” in Inuvo, Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 as filed on February 27, 2025, and our other filings with the SEC. Additionally, forward looking statements are subject to certain risks, trends, and uncertainties including the continued impact of Covid-19 on Inuvo’s business and operations. Inuvo cannot provide assurances that the assumptions upon which these forward-looking statements are based will prove to have been correct. Should one of these risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those expressed or implied in any forward-looking statements, and investors are cautioned not to place undue reliance on these forward-looking statements, which are current only as of this date. Inuvo does not intend to update or revise any forward-looking statements made herein or any other forward-looking statements as a result of new information, future events or otherwise. Inuvo further expressly disclaims any written or oral statements made by a third party regarding the subject matter of this press release. The information which appears on our websites and our social media platforms is not part of this press release.
Inuvo Company Contact: Wally Ruiz Chief Financial Officer Tel (501) 205-8397 wallace.ruiz@inuvo.com
Question for written answer E-001594/2025 to the Commission Rule 144 Tomislav Sokol (PPE)
Immunosenescence, the age-related decline in immune function, increases the vulnerability of older adults to infectious diseases, such as influenza or COVID-19, as well as non-communicable diseases, including cancer. With one third of EU citizens projected to be over 65 by 2100, addressing this challenge becomes even more urgent as immunosenescence reduces both the immune response to infection and the protection provided by influenza vaccination. Despite this, national vaccination strategies often do not fully account for these age-related changes, limiting their impact. With Europe’s ageing demographic, ensuring that vaccination strategies are optimised for older adults is critical for public health and economic sustainability.
In this context:
1.What actions will the Commission undertake to encourage the Member States to adapt their national vaccination programmes to better account for immunosenescence, ensuring older adults receive the most effective and appropriate vaccines available?
2.How does the Commission plan to work with the European Centre for Disease Prevention and Control to develop more specific guidance on age-related vaccine recommendations, ensuring that national immunisation strategies reflect the latest scientific evidence on vaccine effectiveness in older populations?
Source: United States Senator for New Hampshire Maggie Hassan
WASHINGTON – U.S. Senator Maggie Hassan recognized Meenakshi Dwaraka and Salome Castillo Valencia of Nashua as April’s Granite Staters of the Month. Meenakshi and Salome started a free coding class for local students.
Meenakshi and Salome, who are now both in high school, met in sixth grade and have both been interested in coding since they were young. Meenakshi was encouraged by her dad, who is a computer scientist, to develop digital skills, and found that she enjoyed competing in coding competitions. Salome learned how to build websites during the Covid-19 pandemic, and she even sells some of the websites that she creates. The girls noticed that there were not many opportunities to learn computer skills until high school, so they started a fee coding class for students in third grade through fifth grade.
Meenakshi and Salome teach the class at their local community center, and over the weeks attendance has grown. Students in the class learn block coding, basic robotics, and computer safety, giving students the opportunity to learn skills that will eventually help them compete in the 21st century economy. Meenakshi and Salome’s dedication to increasing access to computer skills is an excellent example of the Granite State spirit of sharing knowledge in order to empower others. Their commitment to helping students from all backgrounds prepare for the future – and have fun – is why Senator Hassan named them April’s Granite Staters of the Month.
Senator Hassan launched the “Granite Stater of the Month” initiative in 2017 to recognize outstanding New Hampshire citizens who go above and beyond to help their neighbors and make their communities stronger. To nominate a New Hampshire citizen to be a “Granite Stater of the Month,” constituents can complete the nomination form here.
To read Senator Hassan’s statement for the Congressional Record, see below.
I am honored to recognize Meenakshi Dwaraka and Salome Castillo Valencia of Nashua as April’s Granite Staters of the Month for their work to establish a free coding class for local elementary school students.
Both Meenakshi, 16, and Salome, 17, were interested in coding from a young age. Meenakshi’s dad, a computer scientist, first inspired her to develop digital skills, and she quickly realized that she enjoyed competing in coding competitions. Salome learned how to build websites and code during the Covid-19 pandemic, and has continued to improve her skills and even sell websites that she has created. The girls, who met in sixth grade, noticed that there were not many opportunities to learn computer skills until students entered high school, despite the increasing importance of the field. They decided to help fill this gap by starting a free coding class for students in third grade through fifth grade so that kids from all backgrounds could learn the basics of coding from a young age.
The class, which Meenakshi and Salome teach at their local community center in Nashua, has grown over the weeks. When they first started offering the class, they didn’t have very many students, but over time, they have seen an increase in attendance and interest. Students from different high schools in the area have also reached out to ask for help in starting their own classes and expanding the program. Students in the class learn block coding, basic robotics, and computer safety, giving students the opportunity to learn skills that will eventually help them compete in the 21st century economy.
Meenakshi and Salome’s dedication to increasing access to computer skills is an excellent example of the Granite State spirit of sharing knowledge in order to empower others. Their commitment to helping students from all backgrounds prepare for the future – and have fun– is why I am glad to name them April’s Granite Staters of the Month.
New Zealand’s road freight industry is painting a gloomy picture for business, with only a minority expecting their financial situation to improve over the coming year.
The results are contained in the 2025 National Road Freight Industry Survey, a major survey of 194 respondents across 128 road freight businesses, conducted in March this year by Research NZ on behalf of advocacy group Transporting New Zealand.
The survey was also promoted by the New Zealand Heavy Haulage Association and Groundspread NZ and represents the most extensive industry snapshot in over a decade.
Transporting New Zealand says the survey offers sobering insights into business conditions, the deteriorating road network, and challenges around driver safety and wellbeing.
Only 34 per cent of those surveyed expected their financial situation to improve over the next 12 months, and only one in four respondents reported having sustainable operating margins. Just under half (47 per cent) believed the government was on the right economic track, while 25 per cent disagreed and 27 per cent were unsure.
Transporting New Zealand says the findings echo the concerns it has heard from members and align with wider economic indicators.
“Company liquidations in the transport sector were up by 79 per cent last year, and the ANZ Truckometer Heavy Traffic Index for June 2024 recorded its biggest monthly drop on record, excluding Covid-19 lockdowns.” says Billy Clemens, Transporting New Zealand’s Head of Policy and Advocacy.
“The survey results, combined with the tough economic data, really highlight the need for infrastructure investment from the Government to support growth, as well as resource management reform that helps support new jobs and overseas investment”.
Health, safety, and wellbeing and workforce challenges were also priorities. A total of 78 per cent of respondents called for more purpose-designed rest stops for drivers, and 72 per cent said it was important for drivers to have a good work-life balance.
Finding new drivers was also a big issue. Almost one-half of industry respondents (47 per cent) indicated that “up to 25 per cent” or more would retire or leave the industry in the next five years. This highlighted the ageing workforce.
Concerns about the state of New Zealand’s roads were nearly universal. The vast majority (93 per cent) agreed that poor road maintenance is putting truck drivers and other road users at risk. A significant number (84 per cent), believed that regional roads and bridges are neglected, and that delays in replacing the Cook Strait ferries pose a major risk (79 per cent).
One bright spot in the survey for truck drivers was that while the those in the industry believe the public have a negative perception of professional drivers, that is not the case.
Nearly half of industry respondents (49 per cent) believed the public holds a negative view of professional drivers, while only 20 per cent believed the public viewed them positively.
However, a poll of 1000 New Zealanders conducted by Research NZ painted a more favourable picture, with 52 per cent saying they view professional road freight drivers positively; and only 7 per cent expressing a negative view.
“It’s encouraging to see such widespread public support for truck drivers, and Transporting New Zealand will be highlighting this in our advocacy – especially as we push for better public facilities for drivers and policies that support the long-term sustainability of freight businesses,” says Clemens.